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ABSTRACT 
The majority of prostate cancer (PCa) deaths occur due to the metastatic spread of 
tumour cells to distant organs and the establishment of secondary tumours, 
accounting for more than 3000 deaths per year in Australia alone. Currently, there is 
a lack of effective therapies once tumour cells have spread outside the prostate. It is 
therefore imperative to rapidly develop therapeutics to inhibit the metastatic spread 
of tumour cells in order to promote the survival of men suffering from aggressive 
forms of PCa. The epithelial to mesenchymal transition (EMT) has an established 
role in promoting a migratory and invasive phenotype leading to PCa metastasis, 
making it an attractive therapeutic target. This study aims to develop a cell-based 
multi-parameter primary screening assay that will help identify existing drugs that 
are capable of inhibiting the migratory, invasive and mesenchymal properties of 
invasive and metastatic PCa cells. A drug library that comprises 420 candidates that 
have been approved by the Food and Drug Administration (FDA) was screened. 
Following the completion of the primary screening assay, 39 drugs were identified 
from the library that can either inhibit migration or are cytotoxic to the PC-3 PCa 
cells. Dose response studies were performed to identify the optimal concentration for 
each candidate that can inhibit migration. These concentrations were used to perform 
a series of validation studies which included migration assays using an alternate PCa 
cell line (DU145) as well as invasion assays. Based on the preliminary data obtained 
from the validation studies, mitoxantrone hydrochloride was found to be a strong 
candidate that can inhibit the both migration and invasion of PCa cells without 
significantly affecting cell viability. However further validation studies need to be 
undertaken to confirm the results obtained. By employing the drug repositioning 
strategy instead of the de novo drug discovery and development strategy, the 
potential drug candidate(s) could be rapidly translated into the clinic for the 
management of men with aggressive forms of PCa.  
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Chapter 1: Literature Review 
1.1 Introduction  
The majority of tumour related deaths are due to the metastatic spread of the disease. 
Cell migration plays a significant role in metastasis of prostate cancer (PCa) and may 
be used as a therapeutic target to identify novel treatments for inhibiting PCa 
metastasis (Wells et al. 2013). This review focuses on the current available 
treatments for PCa and the mechanisms of migration involved in PCa metastasis. 
This review will also outline drug repositioning as an alternative strategy to the 
traditional de novo drug development process for identifying novel cancer therapies. 
1.2 Prostate Cancer  
Prostate cancer is a major health challenge being faced by patients, physicians and 
the wider community worldwide. Adenocarcinoma of the prostate is the most 
common cancer in Australian men (excluding non-melanoma skin cancer). There 
were 21,808 new cases in 2009, which accounts for 33% of newly diagnosed cases 
among men. Although the cause of prostate cancer (PCa) is not fully understood, 
research suggests that age, family history, ethnicity, lifestyle and environmental 
factors are risk factors for developing PCa (AIWH 2013).  PCa risk and incidence 
increases with age, whereby 80% of the men diagnosed with PCa are above the age 
of 65 (AIWH 2013; Melman et al. 2011). PCa is responsible for about 3000 deaths 
each year in Australia, making it the second leading cause of cancer related deaths in 
Australian men (AIWH 2013).  
1.3 Prostate Cancer Diagnosis 
PCa diagnosis involves the detection of Prostate Specific Antigen (PSA) levels and 
Digital Rectal Examination (DRE) followed by a transrectal ultrasound (TRUS) 
biopsy if necessary. PSA has gained wide acceptance as a serum tumour marker for 
PCa. An increase in the free PSA levels in the blood (> 4ng/ml) can be used to 
indicate the need of a biopsy for cancer (Garnick 1993; Horwich 2010; Melman et al. 
2011; Jones 2013). DRE is a physical examination whereby the size of the prostate 
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can be estimated along with any irregularities on the surface of the prostate. DRE can 
be used to identify irregularities such as lumps, swellings or hardening of the prostate 
that may indicate the presence of tumours or other problems. While not all tumours 
are palpable, DRE helps identify tumours that do not produce abnormal PSA levels 
and may therefore not be identified using the PSA test alone (AIWH 2013).  
Following positive DRE and PSA results, a TRUS biopsy is performed and is used to 
obtain tissue for histological examination and definitive diagnosis. Once the presence 
of the tumour is confirmed, it is graded. Grading refers to the microscopic 
description of cancer aggressiveness seen within the cells of the prostate tissue under 
the microscope (cancer differentiation), using a system known as the Gleason Score.  
Table 1 Grades of cancer and their risks  
Grade (Gleason Score) Risk for Aggressive Prostate Cancer 
2-6 Low 
7 Intermediate 
8-10 High 
The higher the Gleason score (less differentiated), the more aggressive the cancer is 
and the more likely it is to metastasize and progress to the lethal stage of the disease 
(Drudge-Coates et al. 2012; Peate 2012; Jones 2013).  
Stage is a measure of the spread of the cancer. The stage is summarised using a 
system called the ‘Tumour-Node-Metastasis’ of the TNM staging system. The T-
score represents the extent to which the cancer has spread from the prostate. The N-
score describes if the lymph nodes are involved in the cancer and the M-score 
describes if the cancer has spread to places outside the pelvis such as the bone or the 
brain. A detailed summary of the TNM staging is presented in Table 2 (APCC 
2009).  
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Table 2 Stages of cancer and their extent 
T Stage Spread of Cancer 
TX The tumour cannot be assessed 
T1 The tumour cannot be felt by the doctor or detected by the ultrasound 
T2 The tumour can be felt but it is confined to the prostate as confirmed by 
imaging 
T3 The cancer has spread outside the prostate into the surrounding tissues 
around the prostate  
T4 The cancer has grown into the surrounding organs like the rectum, or the 
bladder 
N Stage Spread of Cancer 
NX It is not known whether the tumour is in lymph nodes 
N0 Tumour has not been found in the lymph nodes 
N1 Tumour has been found in the lymph nodes 
M Stage Spread of Cancer 
MX It is not known whether the tumour is present in distant parts of the body 
M0 No metastases have been found 
M1 Distant metastases has been found 
 
Knowing the stage of the disease can help identify the most optimal treatment for the 
patient and determine the likelihood of the PCa being completely eradicated. Along 
with DRE, PSA and TRUS, various other imaging techniques are employed such as 
bone scan, MRI scan and CT scan to aid in identifying the correct stage and closely 
follow the PCa progression (APCC 2009). Amongst these imaging techniques, 
multiparametric (mp) MRI is gaining importance not only as a diagnostic tool but 
also having a functional multipurpose role in staging, surveillance and therapy 
monitoring (Sankineni et al. 2014).  
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1.4 Prostate Cancer Treatment 
The course of treatment is generally tailored for individual patients, taking into 
account age, health (co-morbidities), life expectancy, personal preference, clinical 
grade and stage of the tumour, potential benefits and risks of the various treatments. 
Due to the heterogenic nature of PCa, there has been a rise in over diagnosis and over 
treatment. As a result, active surveillance is common in patients with low risk PCa 
and primary treatments are delayed until more significant disease presentation 
(Filella et al. 2011). Imaging techniques like mp-MRI along with PSA testing and 
DRE can ensure that the active surveillance is not over done and the window of 
opportunity for treatment still exists (Fenner 2013). Generally, for lower grade PCa 
that is confined within the prostate (termed localised PCa), surgery to remove the 
prostate called radical prostatectomy and/or radiation therapy is used. However in 
many cases the cancer recurs or has been diagnosed after the tumour cells have 
spread beyond the prostate (metastasis) and treatment usually includes androgen 
deprivation therapy (ADT) (Henry et al. 1999). ADT aims to ablate endogenous 
levels of androgen (testosterone) in an effort to deprive the tumour cells of this 
critical growth stimulatory factor (Denmeade et al. 2002).  
 
Figure 1 Treatment options based on the progression of the disease 
This figure provides a summary of the treatment options available for PCa with the tumour 
volume/PSA levels on the Y-axis and the disease progression on the X-axis. Surgery and/radiation 
therapy are the first line of treatment. While most men are cured, about 25% of patients show a 
recurrence of the tumour and are treated with ADT. While ADT is effective, a large number of 
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patients relapse again and develop an androgen independent cancer, also known as CRPC. At the 
stage the cancer is highly metastasised and chemotherapy is the only treatment option available. 
Considering the aggressiveness of the cancer at this point, the therapies simply prolong the 
progression of the disease to a lethal stage. 
ADT is achieved using synthetic oestrogen compounds like diethylsilbestrol (Singer 
et al. 2008) or luteinizing hormone releasing hormone (LHRH) analogues like 
leuprorelin or anti-androgens like bicalutamide (Peate 2012) as well as the new 
generation androgen receptor (AR) targeting drugs like enzalutamide and abiraterone 
(Wong et al. 2014). While ADT seems to be the most efficient treatment, it has 
several side effects such as hyperinsulinemia, obesity, depression, increased risk to 
cardiovascular diseases and other biochemical disorders (Higano 2003; Alibhai et al. 
2006). Despite castrate levels of endogenous androgens, a large number of men fail 
ADT and experience a biochemical recurrence defined by detection of rising PSA 
levels marking progression to an androgen-independent cancer better known as 
castrate resistant prostate cancer (CPRC) and metastasis (De Bono et al. 2010; 
Melman et al. 2011). 
Chemotherapeutic agents, such as Cabazitaxel, and AR targeting drugs like 
abiraterone can be used to treat CRPC, however, these only result in modest survival 
benefits to the patients and ultimately progression to lethal stage disease (De Bono et 
al. 2011; De Bono et al. 2010; Wong et al. 2014). Several other combination 
therapies involving the use of two or more drugs are being investigated to provide 
better survival benefits by overcoming the ongoing problem of drug resistance are 
being investigated and are undergoing clinical trials. One example is the use of 
prednisone with docetaxel as a treatment for CRPC (Tannock et al. 2013) another 
example is the use docetaxel along with zibopentan (Fizazi et al. 2013). For now, 
ADT is the main course of treatment for metastatic cancer but it merely slows the 
progression of the disease without considerably improving the morbidity of the 
patient. The patients typically relapse in about 18–24 months on the initiation of the 
secondary treatment and almost 70% men suffering from metastasis die as a result of 
prostate cancer (Anderson 2003; Drudge-Coates 2005). Most of the deaths related to 
prostate cancer are as a result of metastasis, thereby emphasising a need to find a 
long term and effective treatment for inhibiting PCa metastasis.  
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1.5 Metastasis 
1.5.1 Introduction 
The majority of PCa related deaths are due to the metastatic spread of cancer cells 
and the growth of secondary tumours in vital organs. Tumour metastasis is defined as 
the process by which a malignant cell leaves the primary tumour, travels to a distant 
site via the circulatory system and establishes a secondary tumour (Mundy 2002). It 
involves a series of complicated and sequential steps, termed the metastatic cascade 
(Figure 2). This includes the acquisition of cell motility and invasiveness. Cells first 
dissociate from the primary tumour mass to migrate and invade the surrounding 
extracellular matrix. The invading cells then enter the circulation by intravasating 
into blood or lymphatic vessels. Following their survival and transit in these vessels, 
they extravasate at secondary locations to establish micrometastasis, thereby, 
disseminating to secondary tissue sites. Micrometastasis can consist of a single or a 
few cells that can be dormant for a period of time and then expand into a secondary 
tumour or macrometastasis (Takebe et al. 2011; Thiery 2002). The actual process of 
metastasis is very complex and requires a combination of events to successfully 
develop a secondary tumour or micrometastasis. These events have been sequentially 
explained following the initial development of the primary tumour.  
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Figure 2 The Metastatic Cascade 
(A) Schematic representation of the sequential steps that are involved in the metastatic cascade and 
the establishment of secondary tumours at distant sites. (EMT = Epithelial-mesenchymal-transition; 
MET = Mesenchymal-epithelial-transition.) (B) A representation of the phenotypical changes when 
cells undergo EMT, there is a progressive loss of epithelial characterisctics and a gain of 
mesenchymal characteristics. The most commonly studied epithelial and mesenchymal markers have 
been mentioned here. EMT will be explained in detail in the cell migration section.  
1.5.2 Tumour growth, cell migration and angiogenesis 
As the tumour continues to grow, its demand for oxygen increases and requires the 
formation of new blood vessels (neovascularization). Neovascularisation is known to 
correlate with highly invasive and metastatic PCa. An early study by Weidner et al. 
(1993) shows a relationship between the microvessel density and poor prognosis in 
PCa (Weidner et al. 1993). Carcinogenic transformations and microenvironment 
alterations are known to promote neoangiogenesis and/or lymphangiogenesis as 
outlined in the review by Arya et al. (2006). The synthesis and secretion of pro-
angiogenic substrates and the absence of anti-angiogenic substances also play a key 
role in establishing a capillary or lymphatic network (Jendraschak et al. 1996).  
A 
B 
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The next event in the cascade is acquisition of cell motility and invasiveness. A more 
detailed account for this is outlined in the next section. Cell migration and invasion is 
aided by a number of factors to facilitate the intravasation of the cells into the 
circulatory system which includes stromal interaction and degradation of the stroma 
(Arya et al. 2006). The degradation of surrounding tissue barriers is an important 
factor in aiding the process of metastasis. The main natural tissue barriers are the 
basement membrane and the connective tissues. The tumour cells have to navigate 
through the basement membrane while they leave the primary site and also while 
they intravasate or extravasate from the vasculature. The degradation of these tissues 
is brought about by several groups of proteases; these include the matrix 
metalloprotease (MMP) (John et al. 2001). MMP’s are an important class of peptides 
commonly found in the extracellular matrix (ECM). As highlighted in the study by 
John and Tuszynski (2001), MMP’s play an important role in degrading the 
basement membrane and surrounding stromal tissue barriers. Further, other protease 
families like serine proteases and cysteine proteases are also involved in stromal 
degradation.  With the gain of cellular motility, and aid of various proteases carving 
out the way, the tumour cells intravasate into the circulatory system via the blood or 
the lymph vessels.  
1.5.3 Surviving the immune system and turbulence of circulation 
Once in the circulatory system, the cells have to survive the hostile environment 
brought about by the sheer force and turbulence of the flow. Almost 85% of cells 
undergo death in less than 5 minutes following intravasation (Rosol et al. 2003; 
Msaouel et al. 2008). Several studies show PCa cells have the ability to adhere and 
interact with the platelets and forming fibrin clots that shelter them from the force of 
the blood flow (Arya et al. 2006; Uehara et al. 2003).  Early studies performed by 
Sanda et al. (1995) show that PCa cells have developed mechanisms to escape the 
host immune system. This is brought to light by the fact that PCa cells have a 
reduced expression of the Major Histocompatibility Complex (MHC) Class 1 and 
that the intracellular processing of presented antigens has been altered facilitating the 
loss of tumour recognition (Sanda et al. 1995). Following their survival in the 
circulatory system, the tumour cells find the most conducive environment to 
extravasate and proliferate into a secondary tumour.  
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1.5.4 Non-random homing, extravasation and proliferation 
A study was carried out in Switzerland that shows the different metastatic PCa 
patterns observed in the autopsy reports of almost 1500 men (Bubendorf et al. 2000). 
This study suggests that 90% of the patients had bone metastasis and a very small 
percentage of lung, liver and brain metastases. Several theories have been established 
to understand the non-random homing feature of cancer cells to the specific distant 
sites (bones in case of PCa). These theories have been outlined in detail in the review 
by Msaouel et al. (2008); the first theory is the Paget theory of “seed and soil” which 
states that the cancer cells (seeds) show a preference to the factors of a particular host 
tissue (soil). The second theory by James Ewing is based on the existence of a 
network of vessels known as the Baxton plexus that is responsible for an 
interconnected blood supply system between the prostate and the marrow spaces 
between the vertebral column. Fidler, who combined the two theories, proposed an 
alternative theory (Msaouel et al. 2008). His theory highlighted the possibility of 
heterogeneous subpopulations of cells with different migratory, invasive and 
angiogenic properties. The most recent theory, the homing theory, states that 
different organs have special abilities to attract specific types of cancer cells 
(Msaouel et al. 2008).  These abilities include different chemotactic factors that can 
be specific to cancer cell types. However, Arya et al. suggests a combination of all 
these theories in the metastasis of PCa cells. A detailed account on the suggested 
mechanism of homing, extravasation and tumour proliferation at a distant site 
(especially bone) that best explains PCa metastasis has been mentioned in the review 
(Arya et al. 2006).  
1.6 Cell Migration  
1.6.1 Introduction 
Cell migration plays a vital role in morphogenesis during embryonic development 
and various physiological events such as wound healing and regeneration of fully 
differentiated tissues as well as pathological events such as cancer spread, and other 
diseases (J. et al. 2003). In general, the physiological architecture of cells prevents 
the migration that is necessary for invasion and metastasis. This is especially true in 
epithelial organs like the prostate, where basal stromal cells produce growth factors 
and integrins that anchor the cells to the underlying basement membrane. Epithelial 
 10 Chapter 1: Literature Review 
cadherin (E-cadherin) dominated adherens junction establishes cellular asymmetry. 
Such asymmetric cells are non-motile and proliferation is inhibited by the cadherin 
mediated junctions and other cell-cell communications (Wells 2005). Studies by 
Wang et al. and Wyckoff et al. emphasise that induced motility in the cells is 
responsible for initiation of metastasis before the development of advanced invasive 
tumours (Wang et al. 2004; Wyckoff et al. 2000). This is further supported by 
another study that shows the presence of motile tumour cells in patients suffering 
from non-invasive localised tumours at the time of diagnosis (Cristofanilli et al. 
2004). Imaging studies of tumours have shown that less than 0.1% of the tumour 
cells are motile and are commonly found in localised tumours. Data suggests that 
external factors from the microenvironment also plays a role in promoting cell 
motility (Ahmed et al. 2002). Therefore, two major factors are responsible for cancer 
cells achieving motility, firstly genetic changes (mutations, deletions, fusions, etc.) 
that result in gene expressions of motility regulators and secondly the tumour 
microenvironment (Sahai 2005). 
1.6.2 Molecular mechanisms 
To enable the spread of tumour cells within different tissues, the tumour cell 
migration mechanism must mimic those of normal non-neoplastic cells. The basic 
strategies observed in the non-neoplastic migration mechanisms are preserved in 
tumour motility. The cell body undergoes changes in body shape and migrates 
through the barrier of extracellular matrix (ECM) using it as a substrate.  
Cell migration is highly complicated and comprises many “sub-processes” that are 
carefully organised to achieve the net response of locomotion (Kharait et al. 2005; 
DA et al. 1996). Cells can migrate individually or collectively. The various cell 
migration mechanisms are reviewed here briefly (more comprehensive details can be 
found in elegant reviews by Wells, 2005, Sahai, 2005 and Friedl, 2000). Usually, cell 
locomotion is brought about by a sequential series of steps, whereby cells first 
become polarised (gain directionality) and elongated. Following this, cell protrusions 
are formed as a result of actin polymerisation and these protrusions attach to the 
ECM and bring about cell displacement by detaching the rear end of the cells. These 
protrusions are classified as pseudopodia, filopodia or lammelipodia depending on 
their composition, cellular location, shape and size. Another form of cell locomotion 
involves the formation of cell blebs instead of protrusions. Locomotion is also 
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classified on the ability of the cells to migrate either singularly or collectively. These 
aspects of migration mechanisms are outlined below. 
Mesenchymal mechanism 
Mesenchymal migration is one of the most studied and best understood mechanisms 
of cellular motility. About 10-40% carcinomas use this form of motility to 
metastasise (Thiery 2002). It generally comprises a cycle of four universal steps; 1) 
protrusion of the leading edge (actin polymerization); 2) adhesion to the substratum; 
3) retraction of the rear; and 4) de-adhesion from the substratum (Pollard et al. 2003; 
Yamazaki et al. 2005). As mentioned before, epithelial cells are held together by 
various adhesions; however carcinogenic transformations release these constraints 
thereby enabling cell motility.  
In normal physiology, EMT plays a crucial role in early developmental processes 
such as gastrulation, leading to the formation of the mesoderm (Nisticò et al. 2012). 
EMT activation occurring during neural crest formation is responsible for the release 
of mesenchymal cells that migrate through the body, generate the vertebrate head and 
a wide variety of tissue types, including glial and neuronal cells, adrenal glandular 
tissues, melanocytes, and skeletal and connective tissues (Shook et al. 2003; Nisticò 
et al. 2012). EMT also plays a role in the formation of endocardial cushions (Runyan 
et al. 2005). In adults, EMT plays a role in wound healing, and redeveloping tissues 
that develop postnatally such as mammary glands as well as in pathological 
processes such as inflammation and tumour progression (Nieto 2011; Nisticò et al. 
2012). EMT has established roles in promoting migratory and invasive phenotypes in 
epithelial cancers like PCa (DA et al. 1996; Offermanns et al. 2008). It is a process 
by which epithelial cells lose cell–cell adhesion and acquire mesenchymal properties, 
which include increased motility and invasion (Takebe et al. 2011). The EMT 
program is associated with drastic changes in gene expression as well as phenotype. 
It is responsible for the downregulation of epithelial associated gene expression, such 
as E-cadherin, claudins, epcam and epithelial cytokeratins that facilitates the loss of 
cell adhesion, and the upregulation of mesenchymal associated gene expression such 
as vimentin, snail, slug, zeb and twist family members as well as N-cadherin that 
enhances cell motility (Thiery 2002; Offermanns et al. 2008; Gjerdrum et al. 2011; 
Peinado et al. 2007; Hollier et al. 2009; Shih et al. 2011). The cells achieve 
mesenchymal-like morphology and characteristics, adapting a more 
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“spindlier/fibroblastic” morphology with established polarity (a rear end and a front 
end) and depend on proteolysis to degrade the ECM to provide a path to the motile 
cells (Sahai 2005; Kharait et al. 2005).  EMT can be initiated by numerous cytokines, 
receptor kinases and growth factors that are secreted by the tumours (motogenic 
agents), the most commonly implicated ones are epithelial growth factor (EGF), 
fibroblast growth factor (FGF-1), insulin like growth factor 1 (IGF1) transforming 
growth factor β1 (TGF-β1), c-Met (hepatocyte growth factor), vascular endothelial 
growth factors (VEGF), interleukins (IL) -6, IL-8 and in some cases platelet-derived 
growth factors (PDGF) (Shih et al. 2011). EGF is known to play an important role in 
polarizing the cells as well as determining the speed of cell motility (Harms et al. 
2005; Kharait et al. 2005). Along with the switch to a mesenchymal phenotype the 
EMT program has been reported to endow differentiated cancer cells with stem cell-
like characteristics (Mani et al. 2008), which contribute to metastasis and therapy 
resistance (Hollier et al. 2013). Stromal and accessory cells release several proteases 
such as capain and MMPs that further aid mesenchymal migration. Capain brings 
about the detachment of the cells while MMPs degrade and remodel the ECM 
facilitating the locomotion of the cells through the matrix (Kharait et al. 2005; Wells 
2005). 
While EMT is known to play an important role in promoting migration of the cells 
and their dessemination, its reversion known as mesenchymal to epithelial transition 
(MET) is postulated to play an important role in converting the disseminated tumour 
cells into micrometastases as well as solid secondary tumours at distant sites. 
Together EMT and MET describe the ability of a cell to undergo reversible changes 
during invasion and dissemination and is collectively termed as epithelial 
mesenchymal plasticity (EMP) (Bitting et al. 2014). A review by Bitting et al. (2014) 
outlines the potential roles of EMP in PCa that are known so far and the conspicuous 
questions that need to be answered, however, the exact mechanisms governing EMP 
in the context of PCa metastasis are not yet fully understood.  
Amoeboid mechanism 
Amoeboid motility, a less studied mode of migration, refers to movement of rounded 
or ellipsoid cells. Amoeboid movement in cancer is not very well understood but it 
likely to be similar to mechanisms of migration in leukocytes (Mandeville et al. 
1997). This mode of motility has been observed in various carcinomas like breast, 
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melanoma and prostate (Parri et al. 2009; Taddei et al. 2011; Zeitoun et al. 2012). 
Cells do not adhere or pull on the substrate but rather use a propulsive, pushing mode 
of migration (Friedl et al. 2010). It enables them to squeeze through the ECM (Sahai 
2005; Paňková et al. 2010) or create enough force to deform the matrix (Paňková et 
al. 2010). Unlike the mesenchymal motility, the amoeboid motility does not require 
actin polymerization; it is initiated by increased pressure of the cytoplasm towards 
the cell membrane (Yoshida et al. 2006). Therefore, it does not require the aid of 
proteases to move through the maze of ECM as the cells can easily squeeze through 
the matrix (Figure 3).  
Collective Mechanism 
While the mesenchymal and amoeboid mechanisms mentioned above refer to 
motility of individual cells, several cancer cells migrate collectively as sheets or 
multicellular chains (Sahai 2005; Friedl et al. 2009). Collective motility can be either 
mesenchymal or amoeboid (Figure 3). One major factor that differentiates them 
from single cell motility is that the cell-cell junctions are preserved during the 
movement. Otherwise, the other factors and mechanisms involved in their migration 
are otherwise similar to their single cell counterparts. In a mesenchymal sheet, the 
cells at the front or the leading edge develop lamellipodia and pull the lagging or the 
follower cells (5-10 cells) along (Lecaudey et al. 2008). In some cases, the follower 
cells develop protrusions that are less developed than the leading cell protrusions and 
facilitate quicker migration (Lecaudey et al. 2008). This movement requires a lot of 
coordination amongst the group of cells and this coordination is brought about by the 
cell-cell adhesions (cadherin junctions) as well as various chemical stimuli like the 
presence of cytokine signals in the microenvironment that effect the mesenchymal 
leading cells (Nabeshima et al. 2000; Lecaudey et al. 2006). Cells migrating 
collectively interact closely with the accessory stromal cells in the surrounding that 
release mitotic agents and polarity inducing agents to induce motility and create a 
path through the ECM (Friedl et al. 2008). Similar observations have been made with 
the amoeboid cells where the cells are held together by integrins rather than 
cadherins (Robinson et al. 2003). However the exact precursor of this movement is 
not known as many aspect of amoeboid motility currently remain unexplored (Friedl 
et al. 2003).  
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Figure 3 Mechanisms of cell migration 
(a) Mesenchymal migration. In 3-D matrices, cells form membrane protrusions at the leading edge and 
adhere to the substrate in an integrin-dependent manner. The images show the migration of HT1080 
cells in collagen gels. Arrows indicate membrane protrusions at the leading edge. The red signal 
indicates the backscatter of collagen fibres. (b) Amoeboid migration. Cell-substrate adhesion is weak 
and is independent of integrin function. The images show the migration of DMS79 cells in collagen 
gels. Arrowheads indicate membrane blebbing. The red signal indicates the backscatter of collagen 
fibres. (c) Collective migration. Cells move as sheet-like structures, maintaining cell–cell adhesions. 
The image shows migration of DLD-1 cells on a 2-D substrate. (Figure taken from Yamazaki et al. 
2005) 
1.6.3 Therapies  
Mesenchymal/EMT-mediated cell migration remains the most common mechanism 
by which the tumour cells of epithelial origin such as PCa, acquire cell motility and 
invasiveness to initiate metastasis. Several EMT precursors, as mentioned in chapter 
1.6, can be targeted for therapy development to prevent the progression of the 
metastatic cascade and potentially curb metastasis. However, such EMT-based 
therapies are yet to reach the clinic. Therefore, the targeting of these EMT precursors 
could be used to prevent disease progression by inhibiting tumour motility and lead 
to new therapeutic options for aggressive PCa.  
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1.7 Therapeutic Development and Drug Repositioning 
The process to develop a new therapeutic agent de novo requires very high input of 
time; an average of 10 to 20 years, and money; the pre-approval costs are estimated 
to be on an average 1 to 2 billion USD (Levine 2012; Herper 2012). Despite the 
various novel discovery technologies, there hasn’t been significant progress in terms 
of the time and monetary requirement in drug development. Apart from the long time 
periods and high monetary needs, there is no guarantee that the drug will ever come 
out in the market. More than 90% of the potential drug products are abandoned 
owing to various reasons like insufficient efficacy, serious toxicity or lack of 
appropriate funding (Kola 2008; Ashburn et al. 2004).  
 
Figure 4 Drug development pipeline  
This pipeline represents the various stages of de novo drug development. It also highlights the 
monetary and time requirements of de novo drug development (Mattisson 2008). 
One possible approach for circumventing this situation is drug repositioning. This 
strategy attempts to mine the potential of currently or previously marketed drugs 
with well-known safety profiles to identify new indications and applications for their 
use. As the safety profiles of marketed drugs are generally known, drug repositioning 
has the advantage of mitigating the costs and risks associated with early development 
stage and shorten the route to approval for therapeutic indications (Zikai et al. 2012; 
Ashburn et al. 2004). The strategy is economically attractive when compared with 
the drug development based on the de novo strategy. However, unique challenges are 
associated with repositioning strategies especially with respect to intellectual 
property regarding the drug, and most importantly obtaining the necessary funding 
for a drug that has already been approved or has failed in the past is very difficult as 
a result of the current business mindset and while the USA government organisations 
help fund non-commercial repositioning trials, such aids are not provided in other 
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countries (Novac 2013; Ashburn et al. 2004). Even in the ideal case of no reports 
published about the potential new use of the compound, repositioning of marketed 
compounds could be halted because of the differential pricing policy for different 
indications. There is no incentive for a pharmaceutical company to reposition from a 
low-price indication, such as alcohol abuse or hypertension, to a more expensive one, 
such as oncology, despite the potential medical and financial value for patients 
(Novac 2013). These challenges demand creative approaches and great dedication on 
the part of drug repositioners inside and outside pharmaceutical companies (Ashburn 
et al. 2004).  
There are a number of examples in which coincidence or directed efforts have led to 
successful drug repositioning (Table 3). One prominent example is thalidomide. 
Thalidomide was originally developed by a German company for the treatment of 
nausea and morning sickness in pregnant women. However, as a result of adverse 
side effects, extreme birth defects, extensive research was carried out that lead to the 
development of a new therapeutic indication of anti-angiogenesis. Now, thalidomide 
is commonly used as a treatment for multiple myeloma (Ashburn et al. 2004; 
Sardana et al. 2011). Other successful examples of drug repositioning include 
sildenafil that was originally developed to treat cardiovascular and angina issues 
however, they observed an interesting side effect of the medicine and it was 
thereafter used to treat erectile dysfunction and pulmonary hypertension (Aronson 
2007; Zikai et al. 2012). Some drugs identified by drug repositioning are being 
investigated for different indications. Metformin is one such example, it has been 
widely used in the treatment of type-2 diabetes and has been a part of several pre-
clinical studies wherein metformin is known to kill and radiosensitise breast cancer 
cells and preferentially kills cancer stem cells (Song et al. 2012).  
Table 3 List of drugs that have been successfully repositioned  
Drug Original Indication  New Indication 
Amphotericin   B Fungal infections Leishmaniasis 
Aspirin   Inflammation, pain Antiplatelet 
Bromocriptine  Parkinson’s disease  Diabetes mellitus 
Finasteride  Prostate hyperplasia  Hair loss 
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Gemcitabine  Viral infections Cancer 
Methotrexate   Cancer Psoriasis, rheumatoid arthritis 
Minoxidil  Hypertension Hair loss 
Raloxifene  Cancer  Osteoporosis 
 (Adapted from a white paper by Thomson Reuters, Sep 2012)  
Many drug libraries are comprised of drug candidates that were abandoned as well as 
existing drugs are being developed. While patented drugs could pose a problem when 
it comes to acquiring the compound, it would be very convenient to have such 
libraries ready for use (Novac 2013). One example is the Prestwick library that is 
comprised of almost 1500 non-patented drugs and compounds that have been 
approved by the FDA and other similar agencies. It has been widely used in drug 
repositioning screens (Shahar et al. 2014; Bharadwaj et al. 2014). Recently, several 
studies have been carried out to outline a potentially favourable screen that can 
identify drugs or other compounds based on specific diseases and molecular targets. 
A repositioning technique for Alzheimer’s disease (Corbett et al. 2012) or a different 
rationale of a technique by medical genetics (Wang et al. 2013) are some of the 
recent studies.  
Screening assays refers to a process where large numbers of chemicals are tested 
(i.e., screened) with high efficiency to identify biologically active small molecules as 
candidates for further validation in additional biological or pharmacological 
experiments (An et al. 2010). With the aid of pharmaceutical companies, the 
efficiency and throughput have been greatly improved over the years. High 
throughput screening assays are usually performed in micro well plates (384-well 
plate forms the base standard for high throughput studies) (Liu et al. 2004). The 
screening assays can be widely divided into two types; biochemical assays and cell 
based assays. Cell based assays are a better representative of in vivo and clinical 
situations (An et al. 2010). In addition, cell-based assays allow for the selection of 
compounds that can cross cellular membranes and can also provide indications of 
acute cytotoxicity as an early alert for later stage lead/probe discovery efforts. 
Several factors need to be considered while planning a cell based assay; these include 
the choice of biological system, the choice of assay approach (reporter gene, 
phenotypic or functional) and assay read out modality (An 2009). Screening for 
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multiple parameters also known as high content screening provides more 
information. While cell based assays have some advantages over their biochemical 
counterparts, biochemical assays are the mainstay of high throughput screens in 
general and even in the context of drug repositioning. 
There has been a rise in the number of drug repositioning studies being undertaken, 
most of these screens are based on large high-throughput scale screens requiring 
robotics and other computer-automated techniques often combined with in silico 
involving the use of bioinformatics, to efficiently perform screens of this broad 
nature within a reasonable timeframe (Oprea et al. 2011; Deftereos et al. 2011). 
1.8 Conclusion 
With the increasing age of the Australian population, the number of patients 
suffering from highly aggressive and metastatic forms of PCa is expected to rise. 
Current therapies available for metastatic disease simply prolong the progression of 
the disease to a lethal stage but do not significantly improve the life span of the 
patients. Hence, there is an urgent need to develop therapeutics that can significantly 
improve the morbidity of men suffering from advanced PCa. Acquiring cell motility 
marks the first step of the metastatic cascade. One of the most common mechanisms 
to procure motility is the activation of the EMT pathway. While EMT has been 
established with its role in metastasis, there are no clinical therapies targeting EMT 
available yet. Potentially, by preventing the tumour cells from achieving motility we 
can inhibit the progression of the metastatic cascade and thereby prevent the 
progression of the disease to an advanced and highly metastatic stage of PCa. 
However, drug development is a tedious process that requires very high inputs of 
time and money, after which there is no guarantee that the drug will ever be used in 
the clinic as a therapeutic agent. The drug repositioning strategy helps overcome this 
situation by identifying and developing new indications for existing drugs. As these 
drugs are already in the market, the route to approval is shortened. With the help of 
this strategy, we aim to develop a cell-based multi-parameter primary screening 
assay that can identify existing drugs that inhibit migration, invasion and 
mesenchymal properties of metastatic PCa cells. As sophisticated computer based 
techniques like robotics are not available to many laboratories, we aimed to develop 
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a small-scale, cell-based multi-parameter screen to identify FDA approved drugs 
capable of inhibiting PCa cell migration and invasion. 
1.9  Project Outline 
1.9.1 Objective and hypothesis 
 The underlying objective of my masters’ project was to establish a cell-based, 
multi-parameter screen, which can identify existing drugs that inhibit the 
migratory, invasive and metastatic properties of the PCa cell lines.  
 The hypothesis of my project was that a novel treatment to prevent metastatic 
prostate cancer could be found using the method of drug repositioning. 
1.9.2 Aims 
In light of the objective and hypothesis, the aims of my masters’ studies were: 
 To optimize and develop the primary screening assay; 
 To perform the multi-parameter primary screening assay; and 
 To perform validation studies on the potential candidates identified from the 
primary screen 
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Chapter 2: Materials and Methods 
2.1 Introduction 
This chapter describes the materials and methods that have been used to perform the 
experiments described in this thesis. Any alterations and/or additions to the materials 
and methods specific to work described in a single chapter will be mentioned in that 
chapter.  
2.2 PCa Cell Models  
This study uses the well-established PC-3 and DU145 human PCa cell lines. PC-3 
cells are highly metastatic, migratory and invasive PCa cells. They are non-
responsive to androgens in mice and are commonly used to represent metastatic and 
castration-resistant tumours (Pulukuri et al. 2005). DU145 cells are also highly 
migratory and invasive, however, these cells are weakly metastatic in mice (Tai et al. 
2012). The PC-3 cells for this project have been engineered to create monoclonal 
vimentin transcriptional reporter cells to express Red Fluorescent Protein (RFP) 
under the control of the mesenchymal specific vimentin promoter (Said et al. 2014). 
A monoclonal population of cells was generated by single cell cloning. These cells, 
PC-3
VimRFP
, were previously generated in the Hollier lab. 
 
Figure 5 Engineered PC-3
VimRFP
 Cells 
Diagrammatic representation of creating PC-3 cells that express red fluorescent protein (RFP) under 
the influence of vimentin promoter (Vim Pro). The promoter region highlights AP1: AP1 binding site, 
NE: negative element. NF-κβ: NF-κβ binding site and the arrow indicates the transcription initiation 
site. pDsRed2-N1 is the red fluorescent protein vector. 
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2.3 Cell Culturing Conditions 
PC-3 and DU145 (ATCC) monolayer cell cultures were grown in Roswell Park 
Memorial Institute-1640 (RPMI-1640; Life Technologies, Vic, Aus.) media and 
supplemented with 10% Fetal Bovine Serum (FBS; Life Technologies). These 
cultures were incubated at 37°C and 5% CO2 and the media was changed every two 
days. The cell cultures were passaged by washing the flask with phosphate buffer 
saline (PBS; Life Technologies), detaching the cells with 0.05% Trypsin 
Ethylenediaminetetra-acetic acid (EDTA; Life Technologies) and re-suspended in 
fresh media. The cell number was calculated using the Bio-Rad automated cell 
counter. A PC-3
VimRFP
 cell bank of identical passage cells (passage number 4) was 
generated to reduce screen-to-screen variations. The cells were only passaged up to 6 
times after which a new vial was thawed for each primary screen and used at the 
identical passage number. 
Cells were thawed and transferred into a 15ml tube containing 9ml RPMI media with 
10% FBS. The cells were pelleted by centrifuging at 1535g for 3 minutes. The media 
was aspirated and the pellet was resuspended in 5ml fresh media and pipetted 
thoroughly till the pellet was completely dissolved. The mixture was then transferred 
into a T-25cm
2
 flask. The cells were passaged after alternate days and transferred 
from a T-25cm
2
 flask to a T-75cm
2
 and then eventually from a T-75cm
2
 flask 
(Corning Life Sciences, Australia) into 3 x T-175cm
2
 flasks. Once the cells were 
confluent enough, they were trypsinised and counted. Cryo-media was prepared 
containing 20% FBS, 10% dimethoxysulfoxide (DMSO) and 70% RPMI. The cell 
solution was diluted to 1 x10
6
 cells/ml and 1ml of the mixture added to each cryo-
vial. Vials were then placed in a Mr Frosty Freezing Container (Thermo Fisher 
Scientific, Australia) at -80°C, and transferred to a liquid nitrogen tank after 48hours 
for long term storage. The vials were subsequently thawed and used for the assays as 
required. 
2.4 FDA Drug Library 
An FDA approved drug library that has been commercially developed by Selleck 
Chemicals was used for screening. The library was comprised of 420 drugs that have 
been clinically tested and approved by the FDA. These drugs are drawn from various 
fields, including oncology, cardiology, immunology, and neuropsychiatry. The 
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compounds were supplied in 6 x 96-well plates, each at a concentration of 10mM in 
DMSO. Between 55 and 76 compounds were on each plate. For screening the 
primary assay, a standard concentration of 10μM was used.  
2.5 Monolayer Wound Scratch Migration Assay 
A monolayer wound scratch migration assay using the IncuCyte ZOOM
 
live cell 
imaging system (Essen Biosciences) was performed to quantitate migration. This 
system measures wound closure in real time and calculates the relative wound 
density at each time point. The cells were seeded at a density of 20,000 cells per well 
in 96-well ImageLock plates (Essen Biosciences)
 
and were grown overnight to form 
a confluent monolayer of cells. A WoundMaker
TM 
(Essen Biosciences) was used to 
create uniform, reproducible wounds in all the wells of a 96-well plate (Figure 6). 
After creating the wound, media was aspirated and the wells were washed with fresh 
media at least twice to remove any cells remaining in the scratch area. Following the 
washes, the plates were placed into the IncuCyte ZOOM and scans were scheduled 
for every two hours. Wound closure was monitored over 24 hours and quantified 
with the IncuCyte ZOOM software using the relative wound density metric. RFP was 
also measured using the IncuCyte ZOOM system as readout of the vimentin 
promoter activity of the PC-3
VimRFP 
cells. The software measures total well 
fluorescence, the wound size may affect the total fluorescence. However, this can be 
minimized as the wounds are usually uniform and by using the wound width metric 
of the software we can eliminate the wells with variable wound sizes. Data from each 
well has been graphed as the Object Summed Intensity (RFP intensity) per well.  
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Figure 6 Performing a wound scratch migration assay using the IncuCyte ZOOM system 
(A) This image illustrates the procedure of a wound scratch migration assay using WoundMaker
TM
. 
(Adapted from Essen Biosciences). (B) These are images of the wound scratch assay taken by the 
IncuCyte ZOOM over an interval of 24 hours while testing the effect of DMSO and Cytochalasin D 
on PC-3
VimRFP
 cells. DMSO treated cells showed 90% wound closure whereas cytochalasin D treated 
cells showed less than 20% wound closure. Thus, cytochalasin D arrested migration compared to 
DMSO. This effect is quantitated in (C) that represents the relative wound density measured at the 24 
hour time point. 
2.6 PrestoBlue Cell Viability Test 
The PrestoBlue® (Life Technologies) reagent uses the reducing power of living cells 
to quantitively measure the viability of various human and animal cell lines. 
Resazurin, the active ingredient gets converted to resorufin under the reducing 
environment that is maintained by the living cells. Viable cells continuously convert 
A 
B C 
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resazurin to resofurin, a compound red in colour and highly fluorescent. PrestoBlue® 
was used at 10% volume: volume ratio in cell media (10μL in 100μL sample), 
followed by a 2 hour incubation at 37ᵒC. Total well absorbance was measured at 
570nm; with reference wavelength of 600nm using the FLUOstar Omega (BMG 
Labtech, USA). Media only control was treated with the reagent similarly and the 
average absorbance value was deducted from all the wells as explained in the 
application note protocol.  
2.7 RNA extraction and cDNA synthesis 
RNA was purified from cell pellets using the Direct-zol RNA MiniPrep kit following 
the manufacturer’s protocol (Zymo Research, CA, USA). First strand cDNA 
synthesis was performed using the Superscript III first strand cDNA synthesis kit 
(Life Technologies). cDNA was synthesised by adding 50pM of Oligo (dT) and 
random hexamers to 1000ng of RNA diluted in RNAse free water to 11µL. 
Following a 5 minute incubation at 65°C, a 7µL mixture of 10x reverse transcriptase 
(RT) buffer, Dithiothreitol (DTT; 0.1M), RNaseOUT™ and SuperScript III® RT 
was added. Using a thermal cycle machine (C1000 Touch™ Thermal Cycler, Biorad; 
NSW, Australia), contents were incubated at 25°C for 10 minutes, 50°C for 30 
minutes and 85°C for 5 minutes. The mixture was then incubated at 37°C for 20 
minutes and synthesized cDNA stored at -20°C until further use. 
2.8 Quantitative Real Time PCR (qRT- PCR) 
To analyse mRNA levels, gene specific primer pairs were added to 1µl of cDNA. All 
reactions were performed in triplicate in a 384-well plate (Life Technologies) using 
SYBR® Green (Life Technologies) and a 7500 fast Real-time PCR System (Life 
Technologies). PCR amplification was performed following an initial 10 minute 
denaturation step at 95°C followed by 40 cycles of 95°C for 15 seconds and 60°C for 
60 seconds. A dissociation curve was included in each run to confirm amplification 
of a single gene product. Gene expression was quantified using the 
ΔΔ
Ct method 
(Yuan et al. 2006) relative to untreated cells. RPL32 levels were used to normalize 
the cDNA loading amounts.  The primer sequences used in the study have been 
tested for their efficacy in the laboratory and are described in Table 4. 
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Table 4 EMT primers used in qRT-PCR 
Gene Forward primer Reverse primer 
RPL32 5’- ACTGGGCAGCATGTGCTTTG  3’- GCACCAGTCAGACCGATATG 
E-cadherin 5’- TGCCCAGAAAATGAAAAAGG 3’- GTGTATGTGGCAATGCGTTC 
Snail 5’- CCTCCCTGTCAGATGAGGAC 3’- CCAGGCTGAGGTATTCCTTG 
Slug 5’- GGGGAGAAGCCTTTTTCTTG 3’- TCCTCATGTTTGTGCAGGAG 
Vimentin 5’-GAGAACTTTGCCGTTGAAGC 3’- GCTTCCTGTAGGTGGCAATC 
Zeb 1 5’- TTCCTGGGCTACGACCATAC 3’- TGTGCTCCATCAAGCAATTC  
EpCam 5’- GTGCCGTTGCACTGCTTGGC 3’- GTGCCGTTGCACTGCTTGGC  
NRP1 5’-
TGGTGCTATACTGGGAAGAAGCT
GT 
3’-
AGACTCTGTGACGAGACGTTCTG
TG 
2.9 Statistical Analysis 
The primary screening assay was performed in a 96-well plate format.  Treatments 
replicated in one plate were considered technical replicates, whereas treatments that 
were replicated in different plates but on the same day were considered to be 
biological replicates.  
Z’ factor was used to determine the quality and reproducibility of the primary screen 
whereas the Z score was calculated and used to identify hits. The Z’ factor describes 
the assay quality by determining how well separated the positive and negative 
controls are and also indicate the likelihood of false positives or negatives. Z score is 
the number of standard deviations from the plate mean (excluding controls) for each 
data point which highlights the highly variable data points. It can be used in 
identifying hits (shortlisted candidates) that significantly stand out from the rest of 
the library in terms of inhibiting migration and other parameters.  
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Z’-factor was calculated as follows: 
   
Where, 
σp   is the standard deviation of the positive controls  
σn is the standard deviation of the negative controls 
μp is the mean of the positive controls 
μn is the mean of the negative controls 
The Z’ factor values was used to categorise the quality of a screening assay as shown 
in the table (Zhang et al. 1999).  
Table 5 Categorizing screening assay quality based on Z’ Factor values (Adapted from Zhang et al.) 
Z’ Factor Value Assay Structure Related to screening 
Z = 1 Standard deviation = 0, no variation Ideal assay 
1 > Z ≥ 0.5 Separation band is large Excellent assay 
0.5 > Z > 0 Separation band is small A marginal assay 
Z = 0 
No separation band, the positive and 
negative control variation bands touch 
Not very reliable  
0 > Z 
No separation band, the positive and 
negative control variation bands overlap 
Screening essentially 
impossible 
Z –score was calculated as follows:  
𝑍 − 𝑠𝑐𝑜𝑟𝑒 =  
(𝑥 − 𝜇)
𝜎
 
Where; 
x = data point 
μ = mean 
σ = standard deviation 
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The most common critical z-scores and their corresponding p-values and confidence 
levels are mentioned in Table 6. The mean and standard deviation were calculated 
for each plate excluding controls.  
Table 6 Critical z-scores and the corresponding p-values and confidence levels 
Z-score p-value Confidence level 
< -1.65 or > +1.65 < 0.10 90% 
< -1.96 or > +1.96 < 0.05 95% 
< -2.58 or > +2.58 < 0.01 99% 
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Chapter 3: Optimization and Development 
of the Primary Screening Assay 
3.1 Introduction 
With the increasing age of the Australian population, incidences of PCa are expected 
to rise rapidly over the next decade. PCa metastasis is responsible for the majority of 
PCa related deaths, making it imperative to find new therapeutic agents that can 
significantly improve the survival outcomes of patients with PCa. While the entire 
process of drug discovery de-novo requires very high inputs of time and money with 
no guarantee of bringing a candidate to market, drug repositioning strategies are 
becoming an increasingly attractive alternative. The central objective of this study 
was to develop a cell based multi-parameter primary screening assay that can be used 
to identify FDA approved drugs that inhibit the migration and mesenchymal 
properties of metastatic PCa cells. In addition, this screen also assesses the effect of 
drugs on cell viability to rule out confounding influences of general cytotoxicity on 
screen results. This assay will be carried out in a multiwall plate format using a 96-
well plate. The IncuCyte
TM
 control software can assess the migration responses to 
treatments in real time. In order to monitor the effects on mesenchymal properties 
real time, PC-3 cells were engineered to report changes in expression of an 
introduced vimentin promoter expression construct via RFP expression (PC-3
VimRFP 
cells).  
In order to develop a cell based multi-parameter screen in a microwell plate format a 
number of factors needed to be optimised to establish an effective assay. These 
included: 
 Time course of wound closure by PC-3 cells 
 Effect of genetic manipulation on migration of PC-3VimRFP cells (compared to 
parental cells) 
 Appropriate positive and negative controls 
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 Robust cell viability test that can be performed on a large scale in 96-well 
plates 
 Measurement of vimentin promoter reporter expression using the IncuCyte 
ZOOM software 
Data presented in chapter 4 outlines the results obtained while performing 
experiments to optimize the above-mentioned factors. The cell viability test, positive 
and negative controls were selected and tested. The time course of the proposed 
migration assay, the RFP-vimentin expression and effect of the vehicle compound 
and genetic manipulation on migration were established. Based on the results of all 
the optimized factors, the parameters of the primary screen were finalised and a pilot 
version of the primary screen was evaluated.  
3.2 Materials and Methods 
The common materials and methods have been outlined in chapter 3. Additions and 
alterations to the materials and methods specific to this chapter are outlined below.  
3.2.1 Materials 
PicoGreen was purchased from Life Technologies. Mouse monoclonal anti-vimentin 
antibody (V9 clone), actinomycin D and cytochalasin D were obtained from Sigma 
Aldrich. Secondary anti-mouse-IR800 antibody was purchased from Jomar 
Biosciences whereas DRAQ5 was purchased from Cell Signalling Technologies. 
ImageLock plates were obtained from Essen Biosciences. Mitomycin C and 
nocodazole were purchased from Cell Signaling Technologies as well. Axitinib was 
a part of the FDA drug library. 
3.2.2 InCell WesternTM 
An InCell Western
TM
 (Licor Biosciences) was performed to observe changes in 
vimentin protein expression as well as quantify cell number. The cells were 
permeabilised and fixed using ice-cold 100% methanol. Following PBS washes, the 
cells were incubated with Odyssey blocking buffer (Licor Biosciences) for 2 hours at 
room temperature. After further washes the cells were incubated with anti-vimentin 
antibody (1:2000 dilutions; Sigma-Aldrich) overnight at 4˚C. Following further 
washes, cells were incubated with secondary antibody conjugated with Infrared Dye 
800 CW (Jomar Biosciences) and DNA stained with the nuclear dye, DRAQ-5 
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(1:2000; Cell Signalling Technologies). Plates were then scanned using the Odyssey 
scanner (Licor Biosciences). The DRAQ-5 was measured in the 700nm channel 
whereas the vimentin-antibody conjugate was measured in the 800nm channel 
thereby quantitating DNA content and vimentin expression per well, respectively. 
The DRAQ-5 intensity was used to normalise the vimentin expression to DNA 
content/cell number in each well (Hannoush 2008).  
3.2.3 Quant-iT™ PicoGreen® dsDNA reagent 
PicoGreen (Life Technologies) reagent is an ultrasensitive fluorescent nucleic acid 
stain for quantitating double-stranded (ds) DNA. It can be used as a measure of DNA 
content and cell number. The PicoGreen stock reagent was diluted (1:20) with 20ml 
20X TE buffer. Two hundred microliters of PicoGreen reagent was added to each 
well in a 96-well plate. After an incubation time of approximately 2hours, the plate 
fluorescence was measured at 485/520nm using the FLUOstar Omega plate reader.  
3.2.4 Fluorescence-activated Cell Sorting 
Fluorescence Activated Cell Sorting (FACs) is a specialized type of flow cytometry 
where the cells are sorted into different groups from a heterogeneous mixture one 
cell at a time. The sorting is based on the differences in fluorescence of each cell 
(Cormack et al. 1996). PC-3 cells were grown in a T-25 flask, trypsinized and 
counted. Two million cells for
 each treatment were then suspended in 500μl of PBS 
containing 2% FBS. Cells were then analysed for RFP expression, and RFP positive 
cells were collected for RNA isolation using a Beckman Coulter MoFlo Astrios cell 
sorter. Data was analysed using FlowJo software (Tree Star Inc., USA).  
3.3 Results 
3.3.1 Time course optimization of IncuCyte wound scratch assay 
In order to optimize the time course required to obtain sufficient wound closure a 
preliminary IncuCyte wound scratch migration assay was performed using parental 
PC-3 cells. Following wounding of the cell monolayer, images were collected every 
2 hours and the migration of cells was assessed over a 24-hour period. At the end of 
24 hours, more than 85% wound closure was obtained for the parental PC-3 cells. As 
can be seen in Figure 7 displaying time-lapse images at 6-hour intervals and from 
the relative wound density plot.  
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Figure 7 Time-lapse wound closure observed over a 
period of 24 hours 
(A) The relative wound density monitored over 24 
hours for the parental PC-3 cells following a wound 
scratch migration assay. At the end of 24 hours, 90% 
wound closure was observed. The error bars represent ± 
standard deviation (SD) of n=6 technical replicates in 
one plate. (B) A representative example of the time-
lapse images of wound closure for parental PC-3 cells 
every 6 hours. 
  
A B 
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3.3.2 Influence of proliferation on wound closure 
Once the wound has been created, the cells from the edges migrate towards the 
centre of the wound to reform (heal) the monolayer. However, it is well known that 
proliferative effects can influence the rate of wound closure, which can be dependent 
on the time period of the assay. Therefore, we performed an IncuCyte wound scratch 
migration assay using a pharmacological inhibitor of mitosis to assess the effect of 
proliferation on wound closure over a 24-hour period. Mitomycin C is a DNA cross 
linker and a well-characterized inhibitor of proliferation. A mitomycin C dose 
response assay (0 – 29.9nM) using parental PC-3 cells along with a pre-treatment for 
2 hours (Rahim et al. 2011) revealed there was no inhibition of migration at any 
concentration tested over the 24 hour period (Figure 8A). This suggests that over 
this time period, the proliferation of PC-3 cells has little bearing on the rate of wound 
closure (Figure 8B).  
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Figure 8 Proliferation does not confound the PC-3
VimRFP
 wound scratch migration assay 
The PC-3
VimRFP
 cells were treated with mitomycin C at the given concentrations and underwent the 
wound scratch migration assay. (A) Relative wound density observed over a period of 24 hours in the 
absence (blank) or presence of mitomycin C at various concentrations are not significantly different (p 
> 0.82; one way ANOVA multiple comparisons test). Some wells were pre-treated with mitomycin C 
at 29.9nM for 2 hours before commencing the wound scratch assay. The error bars represent ±SD of 
n=4 technical replicates for each treatment. (B) Wound scratch images at the 0 hour and 24 hour time 
points for each treatment. The scale represents 300 µm. No significant changes in migration were 
observed in the presence of mitomycin C over a period of 24 hours. 
A 
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3.3.3 Effect of genetic manipulation 
As mentioned above, the PC-3 cells being used for this study have been genetically 
engineered to express RFP under the influence of the vimentin promoter. A wound 
scratch migration assay using the IncuCyte ZOOM live imaging system was carried 
out comparing the rates of cell migration between the PC-3
VimRFP
 cells and the 
parental, non-engineered PC-3 cells. As seen in Figure 9 no significant differences 
were observed in the rates of migration for the PC-3
VimRFP
 cells compared to their 
parental counterparts over a period of 24hours. 
3.3.4 Identification of an appropriate positive control for inhibition of PC-3 
migration 
A positive control for the multi parameter primary screening assay would be a 
compound that inhibits migration of the PC-3
VimRFP
 cells without affecting the cell 
viability. Based on the literature and previous experiments performed in our 
laboratory, cytochalasin D (Kai et al. 2013), actinomycin D (used in the lab for human 
PCa line LNCaP), nocodazole (Zhu et al. 2010) and axitinib (Lou et al. 2014) were 
selected as potential candidates for the positive inhibitory control. Migration assays 
were performed to identify the most potent migration inhibitor that did not 
significantly alter cell morphology or reduce viability. Several concentrations were 
selected for each candidate for their specific effect on PC-3 cell migration. It was 
observed that axitinib (tyrosine kinase inhibitor) did not inhibit migration even at the 
highest concentration tested (10µM; Figure 10). Actinomycin D (antineoplastic 
alkylating agent) showed some inhibition at higher concentrations along with some 
possibility of reduced cell viability; however there was still substantial wound closure 
even at the highest concentration tested (Figure 11). Nocodazole (antineoplastic) and 
Cytochalasin D (anti-actin) showed the most prominent inhibition of migration across 
a range of concentrations tested. However, at high concentrations, both compounds 
induced considerable cell toxicity. This can be seen in wound scratch images whereby 
at higher concentrations of nocodazole and cytochalasin D numerous cells appeared to 
have taken on a spindly morphology (Figure 12B) or rounded up and detached from 
the plate, signs of cell death (Figure 13B). At lower concentrations, nocodazole had 
less toxic effects but did not inhibit migration (Figure 12A). However, at a 
concentration of 0.197nM, cytochalasin D showed effective cell migration inhibition 
without affecting cell viability (Figure 13A; Figure 26B for viability data). 
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Figure 9 Genetic engineering does not influence PC-3
VimRFP
 wound scratch migration assay 
A wound scratch migration assay was performed to compare the migration profiles between the 
parental PC-3 and PC-3
VimRFP
 cells. (A) Relative wound density for parental PC-3 and PC-3
VimRFP
 cells 
over a period of 24 hours is not significantly different. The error bars represent ±SD of n=8 for each 
condition and the unpaired t-test was used. (B) Wound closure at 0 hour and 24 hour time points. No 
significant change in migration was observed. The scale represents 300µm.  
  
A 
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Figure 10 Axitinib as a potential positive control for the primary screening assay 
The PC-3
VimRFP
 cells were treated at given concentrations of axitinib and underwent the wound scratch 
migration assay. (A) Relative wound density observed for the indicated concentrations of axitinib over 
a period of 24 hours are not significantly different from blank. The error bars represent ±SD of n=4 
technical replicates for each treatment and the one way ANOVA multiple comparison test was used to 
calculate p values. (B) Wound scratch images taken at the 0-hour and 24-hour time points followed by 
a magnified image of the 24-hour time point to monitor morphology changes. The scale represents 
300µm. Axitinib does not inhibit migration even at the highest concentration.   
A 
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Figure 11 Actinomycin D as a potential positive control for the primary screening assay 
The PC-3
VimRFP
 cells were treated at given concentrations of actinomycin D and underwent the wound 
scratch migration assay. (A) Relative wound density observed for the indicated concentrations of 
actinomycin D over a period of 24 hours. At 0.4 nM, 0.08 nM and 0.04 nM, the wound closure 
inhibition is significantly greater (*; p < 0.02) as opposed to 0.008 nM. The error bars represent ±SD 
of n=4 technical replicates for each treatment and the one way ANOVA multiple comparison test was 
used. (B) Wound scratch images taken at the 0-hour and 24-hour time points followed by a magnified 
image of the 24-hour time point to monitor morphology changes. The scale represents 300µm. At 
higher concentration (0.4nM and 0.08nM) there is a change in morphology that may imply reduction 
in viability. At lower concentrations (0.04nM and 0.008nM) migration inhibition is observed. 
However, the wound closure is still greater than 50% which does not indicate sufficient inhibition to 
use actinomycin D as a positive control. 
  
A 
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Figure 12 Nocodazole as a potential positive control for the primary screening assay 
The PC-3
VimRFP
 cells were treated at given concentrations of nocodazole and underwent the wound 
scratch migration assay. (A) Relative wound density observed for the indicated concentrations of 
nocodazole over a period of 24 hours. At 1.66 nM, 0.33nM and 0.16nM, the wound closure inhibition 
is significantly greater (*; p < 0.008) than that for 0.033nM. The error bars represent ±SD of n=4 
technical replicates for each treatment and one way ANOVA multiple comparisons test was used. (B) 
Wound scratch images taken at the 0-hour and 24-hour time points followed by a magnified image of 
the 24-hour time point to monitor morphology changes. The scale represents 300µm.  Nocodazole at 
high concentrations seems to be extremely cytotoxic to the cells as seen by the changes in cell 
morphology, except at the lowest concentration (0.033nM). However, the inhibition observed at 
0.033nM is not sufficient to be used as a positive control.  
A 
B 
 40 Chapter 3: Optimization and Development of the Primary Screening Assay 
  
 
Figure 13 Cytochalasin D as a potential positive control for the primary screening assay 
The PC-3
VimRFP
 cells were treated at given concentrations of nocodazole and underwent the wound 
scratch migration assay. (A) Relative wound density observed for the indicated concentrations of 
cytochalasin D over a period of 24 hours shows a significant reduction in wound closure (*; p < 
0.001). The error bars represent ±SD of n=4 technical replicates for each treatment and the one way 
ANOVA multiple comparison test was used. (B) Wound scratch images taken at the 0-hour and 24-
hour time points followed by a magnified image of the 24-hour time point to monitor morphology 
changes. The scale represents 300µm. At higher concentrations, cytochalasin D seems to be highly 
cytotoxic as inferred by the rounding up of the cells, however at the lowest concentration. 0.197nM 
the cells seem to tolerate the dose and provide a sufficient inhibition of migration (wound closure is 
less than 20%) . 
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3.3.6 Effect of vehicle control on migration 
The FDA drug library to be screened comprises of drugs diluted in DMSO. The 
drugs will be diluted by a thousand fold to get the required concentration of 10µM, 
and thus DMSO will be present at a concentration of 0.1%. The main objective of 
this assay was to determine the effect of 0.1% DMSO on migration of PC-3
VimRFP
 
cells. In case 0.1% DMSO does effect the migration of the PC-3 cells, a dose 
response study was performed to identify the optimal DMSO concentration. A 
migration assay was performed in the presence of DMSO concentrations ranging 
from 1% to 0.00001%. No change in migration was observed, even at the highest 
concentration (1%) of DMSO (Figure 14). 
3.3.7 Assessment of cell viability following the wound scratch assay 
Cell viability is the second parameter that is to be included in the primary screen. 
Assessment of cell viability will be important to ensure that any inhibition of 
migration observed by the drugs is not simply an artifact of cell viability differences. 
While not the main focus of this particular study, this would also allow us to identify 
novel FDA approved drugs that could potentially be used as cytotoxic/anti-cancer 
agents for metastatic castrate resistant PCa.  
Two cell viability reagents, PicoGreen and PrestoBlue, were assessed to identify the 
most suitable viability test. A group of 9 drugs along with the controls were subject 
to PrestoBlue and PicoGreen cell viability tests following a wound scratch migration 
assay. The results were normalised to the reference wavelength and made relative to 
the negative control, DMSO. These results can be viewed in Figure 15. Z-scores 
were calculated for the data using the formula provided in chapter 2.9 (Figure 16). 
As can be observed Figure 16A, the Z-scores for most of the drugs do not vary 
significantly other than the scores for bortezomib and mitoxantrone. There were 
contradicting results for these two drugs between PrestoBlue and PicoGreen assays, 
whereby there was a substantial decrease and increase observed for these drugs, 
respectively measured (Figure 15). As can be seen from the images in Figure 16B, 
PC-3 cells in the presence of bortezomib and mitoxantrone look stressed and are 
rounding up from the plate, indicating cell toxicity. However, the PicoGreen assay 
shows a very high z score suggesting these drugs increased viability rather than have 
a cytotoxic effect. PrestoBlue on the other hand correctly identified these drugs as 
cytotoxic.  
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Figure 14 Vehicle control, DMSO, does not inhibit PC-3
VimRFP
 migration  
The PC-3VimRFP cells were treated with different concentrations of DMSO and underwent thte 
wound scratch migration assay. (A) Wound closure over 24 hours in the presence of DMSO at various 
concentrations and in the absence (black) of the vehicle control is not significantly different (p > 
0.99). The error bars represent ±SD of n=6 technical replicates for each treatment the one way 
ANOVA multiple comparison test was used to calculate p values. (B) This figure shows images of the 
wound scratch at 0 hour and 24 hour time points in the presence of the different concentrations of 
DMSO. The scale represents 300µm. No change in wound closure was observed in the presence of 
DMSO even at the highest concentration of 1%. 
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Figure 15 Assessing potential cell viability tests to be included in the primary screening assay 
The PC-3
VimRFP
 cells were treated with a panel of 8 drugs from the library and underwent the wound 
scratch migration assay. After 24 hours, one plate was subject to PicoGreen assay whereas the other 
was subject to the PrestoBlue assay. The viability data from both the assays were calculated and made 
relative to DMSO. Most of the drugs showed similar viability measures as calculated by the two 
assays, except two.  (A) The PicoGreen assay data indicates high viability values for mitoxantrone and 
bortezomib (indicated with an asterisk). (B) The PrestoBlue assay data relative to DMSO that 
indicates low viability values for mitoxantrone and bortezomib (indicated with an asterisk). The error 
bars represent ±SD for n=3 technical replicates for each treatment. 
  
A 
B 
 44 Chapter 3: Optimization and Development of the Primary Screening Assay 
 
 
 
Figure 16 Comparing the PicoGreen and PrestoBlue viability data  
The PC-3
VimRFP
 cells were treated with 8 drugs from the library and underwent the wound scratch 
migration assay. After 24 hours, one plate was subject to the PicoGreen assay whereas the other was 
subject to the PrestoBlue assay to assess cell viability. The viability data from both the assays were 
calculated and made relative to DMSO. (A) Z-scores for the panel of treatments calculated following 
measurement of cell viability using the by PicoGreen and PrestoBlue tests show that the resultant 
scores for mitoxantrone and bortezomib between the two assays are divergent. (B) Images taken at the 
0 hour and 24 hour time points in a wound scratch assay show that cells treated with mitoxantrone 
appear distressed whereas the cells treated with bortezomib appear to be rounding up, indicating that 
these treatments are cytotoxic. The scale represents 300 µm. Viability assessment by the PrestoBlue 
assay correctly identifies these drugs as toxic (reduction in viability) whereas PicoGreen indicates an 
increased viability for them. 
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3.3.8 Assessment of vimentin-RFP expression using the IncuCyte ZOOM 
The IncuCyte ZOOM software has the ability to measure and quantify the RFP 
intensity present in each well which in turn can quantitate changes in the reporter 
expression. This can be achieved using the red intensity per well metric provided by 
the IncuCyte
TM 
control software. Four drugs from the library were selected that were 
expected to regulate vimentin expression to assess RFP expression in PC-3
VimRFP
 
cells using the IncuCyte ZOOM. They were selected based on the migration results 
following a wound scratch assay. Rapamycin showed almost 90% wound closure 
whereas vorinostat, simvastatin and maprotilline showed varying degrees of 
migration inhibition. The red fluorescence intensity from the wells can be seen 
Figure 17A after a period of 24 hours following a wound scratch assay in the 
presence of the indicated drugs. The raw intensity data calculated from the 
IncuCyte
TM 
control software was made relative to DMSO, the negative control 
(Figure 17B). The wound scratch images at the 24 hour time point showed that 
simvastatin, vorinostat and maprotilline inhibited migration whereas rapamycin 
showed an almost 90% wound closure. Based on the migration results, we expected 
to observe a decrease in RFP intensity for simvastatin, vorinostat and maprotilline 
and RFP intensity similar to DMSO (negative control) for rapamycin. However, 
maprotilline and rapamycin showed lower levels of RFP expression whereas 
vorinostat and simvastatin showed higher levels of RFP expression (greater than the 
negative control). Although not very obvious, on closer inspection one can see a 
lower RFP intensity in the red fluorescence image for rapamycin, while no prominent 
changes can be visually observed for the other treatments. 
3.3.9 Comparison of IncuCyte ZOOM Vimentin-RFP quantification with RFP 
expression via FACS and endogenous vimentin mRNA levels 
Vimentin is a common mesenchymal marker that is responsible for changes in the 
type III intermediate filaments that correlates with mesenchymal shape and cell 
motility (Mendez et al. 2010; Leader et al. 1987). Mendez et al (2010) showed a 
relation between these intermediate filaments and increased mesenchymal phenotype 
and motility. Vimentin expression is regulated by a range of factors and one of these 
influencing factors is the promoter region of vimentin, which activates the reporter 
expression in the PC-3
VimRFP
 cells. The IncuCyte ZOOM system, measures the total 
RFP intensity of the well and this in turn can be used to quantitate the changes in   
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Figure 17 RFP Expression measured by IncuCyte ZOOM 
(A) Wound scratch images taken at the 24-hour time point. The images of each treatment can be 
viewed as phase contrast, red fluorescence and an overlay of the two. The scale represents 300 µm. 
Rapamycin does not inhibit reduce migration, whereas the other three drugs show a visible inhibition. 
The IncuCyte ZOOM software measures the red intensity per well. (B) The RFP expression made 
relative to the negative control (DMSO) as measured by the IncuCyte
TM
 control software (no error 
bars as n=1). The RFP intensity measured was highest in simvastatin, followed by vorinostat, 
maprotilline and rapamycin. 
A 
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vimentin brought about by the particular promoter region to which the reporter is 
attached. However, as observed in 3.3.9, the reporter expression did not match up to 
our expectations with the migration assay. As a result, an experiment was designed to 
validate the changes in reporter expression as observed by the IncuCyte ZOOM 
when treated with the four drugs; maprotilline, rapamycin, simvastatin and 
vorinostat. FACS was performed to identify changes in the RFP intensity observed 
by the IncuCyte ZOOM. The reporter expression was further compared to the 
changes in the endogenous vimentin expression by performing a qRT-PCR. Cells 
were seeded at the same density as in wound scratch migration assays and harvested 
following 24-hour incubation with the respective drugs. The RFP intensity of 
individual cells was quantified using FACS analysis (Figure 18). Thereafter, RFP-
positive cells were collected for RNA isolation. The RFP intensity of individual cells 
following the drug treatment for 24 hours was quantified using the cell sorter. All 
treatments showed a higher RFP expression than DMSO. Simvastatin showed the 
least intensity, followed by rapamycin and maprotilline with RFP intensity higher 
than simvastatin and vorinostat with the highest intensity. Once the RFP intensity 
was measured, the cells were collected and subject to RNA extraction and cDNA 
preparation. The cDNA was then used to perform a qRT-PCR to assess changes in 
the endogenous vimentin expression. The vimentin expression was normalised across 
all treatments and DMSO control groups (Figure 19A). Maprotilline and simvastatin 
showed the lowest expression, followed by rapamycin and SAHA that showcased a 
higher vimentin expression. The data obtained from FACS and qRT-PCR was 
compared to the RFP expression obtained from IncuCyte ZOOM. As can be 
observed in Figure 19B, the data across all three experiments is variable and shows 
no particular pattern.   
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Figure 18 RFP intensity measured using the FACS cell sorter system 
The PC-3
VimRFP
 cells were treated with 4 drugs for 24 hours and then underwent FACS (A) 
Histograms show the difference in RFP intensity for the parental PC-3 and the PC-3
VimRFP
 cells. 
Parental cells show no RFP intensity whereas the PC-3
VimRFP
 cells show a shift in the peak that 
represents the presence of RFP expression. (B) These histograms demonstrate the effect on RFP 
intensity of PC-3
VimRFP
 cells when treated with the indicated drugs. The mean fluorescence intensity 
(MFI) was calculated from the histograms (n = 1). 
 
MFI = 4.85 MFI = 4156 
MFI = 4687 MFI = 6483 MFI = 6051 
MFI = 10410 MFI = 5370 
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Figure 19 Comparing vimentin/reporter expression using three different methods 
The PC-3VimRFP cells were treated with a panel of drugs for 24 hours, the RFP intensity was 
assessed using IncuCyte ZOOM and FACS. A qRT-PCR was also performed to assess the 
endogenous vimentin expression. (A) This histogram represents the vimentin endogenous expression 
obtained from the qRT-PCR, the fold changes have been made relative to DMSO. (B) FACS 
determined the MFI for each treatment that was made relative to DMSO. (C) The data obtained from 
the IncuCyte ZOOM system, FACS and qRT-PCR are compared together. The vimentin/reporter 
expression determined by each technique is different and does not show any pattern or correlation 
(n=1 for each assay).  
A 
B 
C 
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3.3.10 Testing vimentin protein expression using In Cell Western as an alternative 
method to assess changes in the vimentin level 
Given the ambiguous results concerning vimentin-RFP expression, measurement of 
vimentin protein levels was assessed as an alternative to monitor vimentin and 
therefore the mesenchymal phenotype. Given the nature of the screening assay, a 
suitable technique that could be performed in situ in 96-well plates following the 
wound scratch assay was needed. As a result, the In-Cell Western™ assay was 
assessed to quantitate vimentin protein expression and thereby potentially be 
incorporated in the primary screen workflow. The In-Cell Western™ assay was 
carried out for a 96-well plate comprising 33 drug treatments following a wound 
scratch assay. Figure 20A shows images taken by the Odyssey at both 700nm and 
800nm for a 96-well plate. Figure 20B shows that none of the treatments has a 
vimentin expression lower than 75%. The lack of significant change in vimentin 
expression was further verified by Figure 20C that displays the z-scores of 33 drug 
treatments.  
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Figure 20 Vimentin protein expression determined with the InCell Western assay to potentially assess 
changes in the mesenchymal phenotype of the PC-3
VimRFP
 cells 
A wound scratch migration assay was performed for 33 drugs from the drug library, following which 
the cells underwent an InCell Western assay. (A) The fluorescence images as taken by the software; 
DRAQ5 appears red in the 700nm channel whereas the vimentin expression appears green in the 
800nm channel. (B) Normalised vimentin protein expression shows that the treatments do not cause a 
significantly different change in the vimentin protein level. (C) Z-scores for all 33 treatments confirm 
that no significant changes have been observed over a period of 24 hours (No error bars, n=1).  
B 
A 
C 
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3.3.11 Multi parameter pilot screening assay 
Based on the results obtained throughout previous optimization studies, a preliminary 
small-scale pilot-screening assay was set up to monitor and quantitate the following 
parameters: 
a. Migration of the cells by measuring relative wound density (IncuCyte 
ZOOM) 
b. Transcriptional vimentin expression by measuring the RFP intensity 
(IncuCyte ZOOM) 
c. Cell viability using PrestoBlue reagent 
3.3.12 Pilot assay quality  
The pilot screen mentioned in the previous section was successfully performed. As 
mentioned in chapter 2.9, Z’ Factor is used to establish the quality and 
reproducibility of an assay. The migration data from the pilot screen was used to 
measure these characteristics. The Z’ factor for the two replicates were calculated 
and are shown in the table below.   
Table 7 Z’ factors of the plates that were part of the pilot study 
Plate Number Z’ factor 
1 0.846939348 
2 0.527939293 
As the Z’ factor is greater than 0.5, the assay is of good quality and can be 
reproduced with accuracy.  
3.4 Discussion 
The objective of the work presented in this chapter was to optimize a number of 
parameters to enable the successful development a high throughput multi parameter 
primary screening assay to identify drugs that can inhibit the migratory and 
mesenchymal properties of the metastatic PC-3 PCa cell line. PC-3 cells are highly 
migratory, which was verified using the IncuCyte ZOOM wound scratch assay with 
more than 85% wound closure over 24 hours. Thus, PC-3 cells are a suitable model 
to interrogate drugs to inhibit cell migration.   
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The wound scratch migration assay is a common technique to assess cell migration in 
vitro. It is based on the observation that upon creation of an artificial gap, the so 
called ‘‘scratch” or “wound’’, on a confluent cell monolayer, the cells subsequently 
conceal the exposed surface. Cells surrounding the wound release several autocrine 
factors that promote cell migration and in some cases cell proliferation to fill up the 
empty wound.  The cells on the edge of the newly created gap will move toward the 
opening to close the ‘‘scratch’’ until new cell–cell contacts are established again. 
This scratch was traditionally performed with the aid of a micropipette tip. The entire 
process is described in a protocol by Liang et al. (2007), which also outlines the 
advantages and limitations of this technique (Liang et al. 2007). While it is a quick, 
simple and an economical assay, it has several limitations such as its inability to be 
performed in a high-throughput manner, as individual scratches need to be created.  
The IncuCyte system is a live cell imager that can be installed in the incubator. It 
eases the process of wound creation by providing users with a device known as the 
WoundMaker
TM
. This device can simultaneously create uniform scratches over a 
monolayer of cells in each well of a 96-well plate. The IncuCyte ZOOM system not 
only allows a high-throughput approach to the wound scratch assay but also provides 
an appropriate software and metrics that can take images every few hours and aid 
with the analysis. The relative wound density metric of the IncuCyte
TM
 control 
software measures the changes in cell density within the wound as well as the area 
outside the wound to quantify wound closure in the form of relative wound density. 
While relative wound density measures cell density, it does not differentiate between 
wound closure by proliferation and migration. It is therefore essential to ensure that 
the wound closure observed is a result of cell migration and not cell proliferation. 
This was achieved by treating the cells with a proliferation inhibitor, enabling the 
assessment of the effect of proliferation on wound closure over the assay period. 
Mitomycin C has been regularly used in the laboratory to inhibit cell proliferation. It 
is an alkylating agent and thereby prevents proliferation. Studies carried out by Kang 
et al. in 2001 show that mitomycin C inhibits proliferation in a dose dependant 
manner. It has been reported in the literature that mitomycin C inhibits proliferation 
at lower concentration and induces cell death at concentrations higher than 10μg/ml 
(29.9nM) which supports the use of 29.9nM as the highest concentrations for the 
experiment (Kang et al. 2001). The PC-3
VimRFP
 cells were treated with various 
concentrations of mitomycin C and a small number of wells in the 96-well 
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ImageLock plate were pre-treated with mitomycin C at 10μg/ml for two hours before 
commencing the wound scratch assay. No significant changes in the migration 
pattern of the cells were observed with the addition of the inhibitor (Figure 8). This 
suggests that proliferation does not play a significant role in wound closure over a 
relatively short time period of 24 hours using the PC-3 model. However, if the time 
period of the assay were extended, the contribution of proliferation to wound closure 
would likely increase. 
Genetically modified PC-3
VimRFP
 cells were used to perform the primary assay. I 
investigated whether the incorporation of the vimentin promoter reporter construct 
affected the migratory properties of the PC-3
VimRFP
 cells when compared to their 
parental counterparts. As observed in Figure 9 the PC-3
VimRFP 
cells did not show any 
variation in their migration profiles when compared to their parental counterparts. 
The addition of a reporter to the PC-3 cells does not change their migratory 
properties, therefore, the PC-3
VimRFP
 cells can represent the general PC-3 population 
that are highly migratory and invasive. 
The major objective of the primary screening assay is to identify drugs that 
specifically inhibit cell migration. Hence, potentially any compound that is known to 
inhibit migration of PC-3 cells without substantially affecting their cell viability 
could be used as a positive (inhibitory) control for the primary screen. Based on the 
previous experiments performed in the laboratory, actinomycin D and nocodazole 
were selected as candidates for the positive control. Previous reports in the literature 
also identified cytochalasin D and axitinib as potential candidates that inhibit 
migration in PCa cells (Kai et al. 2013; Lou et al. 2014). However, all the past 
experiments and most of the literature are based on studies using PCa cell lines other 
than PC-3 cells. Using the literature as a guide to identify concentration ranges for 
the selected drugs, I examined these potential positive control treatments in a dose 
dependent manner. It was observed that neither axitinib nor actinomycin D inhibited 
migration; the wound closure was on par with cells without any treatments (Figure 
12; Figure 13). Nocodazole on the other hand proved to be highly cytotoxic at 
higher concentrations (cells rounding up and detaching from the plate can be seen in 
the wound scratch images) whereas it did not significantly inhibit migration at lower 
concentrations (Figure 14). Cytochalasin D was also found to induce cell rounding at 
high concentrations, but at lower concentrations this effect was absent and cells 
resembled those in vehicle control wells (Figure 15). At a concentration of 0.197nM 
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the cell morphology looked healthy and migration was restricted to less than 20% 
wound closure. Based on this, 00.197nM cytochalasin D was selected as the positive 
inhibitory control (hereafter referred as the positive control). 
The drugs from the FDA drug library were set to be used at a concentration of 10 µM 
for the primary screen. While 10μM is a standard concentration for screening assays 
(within the μM range (Lipinski et al. 2012)), it is much higher than the IC50 values 
of most drugs, although not specific to PC-3 cells. This concentration was selected 
for the ease of performing the screen at a single concentration and to ensure that 
weakly positive candidates that might require high concentrations to discern the 
desired effect of migration inhibition were not missed. 
The drugs from the FDA drug library were dissolved in DMSO at a concentration of 
10mM. DMSO is a commonly used reagent for the cryopreservation of cell lines as 
well as a solvent for several drugs. Despite its widespread use, DMSO is known to be 
toxic at concentrations higher than 10% (V:V), and recent data suggests that DMSO 
can be cytotoxic even at concentrations as low as 2% (Galvao et al. 2014). It was 
therefore imperative to assess the effect of DMSO on the PC-3
VimRFP
 cells. The 
DMSO concentration of interest is 0.1% as the drugs will be diluted 1000-fold to a 
concentration of 10μM for the primary screening assay. In case 0.1% DMSO does 
effect cell migration, a wound scratch assay concentration response study was 
performed using DMSO concentrations ranging from 1% to 0.00001% in order to 
identify the optimal DMSO concentration. After 24 hours, it was observed that even 
a relatively high concentration of 1%, DMSO had little or no effect on the migration 
of the PC-3
VimRFP
 cells (Figure 16). Importantly, 0.1% DMSO was observed to have 
little impact on PC-3 cell migration with almost 90% wound closure after 24 hours 
(Figure 16). Based on this data, it can be inferred that any changes in migration or 
viability observed during the primary screen using 0.1% DMSO are as a result of the 
drug treatment. Therefore, this concentration will be used as the negative vehicle 
control while performing the primary screen. 
One of the important factors when identifying hits from the primary assay is that the 
drug does not significantly affect the cell viability. Cell viability is the second 
parameter in the primary assay and is an important consideration to assess the 
involvement of cytotoxicity or cell death in inhibition of migration. Two commonly 
used cell viability/proliferation tests were assessed to identify the most suitable assay 
amenable to the primary screen carried out in 96-well plate format (1.3.5). 
 56 Chapter 3: Optimization and Development of the Primary Screening Assay 
PrestoBlue reagent is very similar to the widely used AlamarBlue reagent in terms of 
active compounds. Also, a recent study claims that both the reagents offer similar 
and equally good results when measuring cell viability (Martín-Navarro et al. 2014). 
However, PrestoBlue requires a shorter incubation period and as a result, was 
preferred as a candidate for the cell viability test. PicoGreen on the other hand is a 
very common ds-DNA quantitating reagent. PicoGreen is not commonly used to 
measure cell viability but it is used to quantitate ds-DNA, which in turn can be used 
to infer cell number/ proliferation. It must be noted that both the reagents are indirect 
measures of viability and are strongly affected by proliferation rate and seeding 
density. The results as observed in Figure 17 show some irregularities with the 
PicoGreen readings regarding cytotoxic treatments like bortezomib and mitoxantrone 
hydrochloride. PicoGreen shows very high values for these compounds despite clear 
cytotoxic effects. One possible explanation for this observation could be that the 
manufacturer’s protocol available for the PicoGreen reagent states an optional step 
that involves lysing the cells before adding PicoGreen. This step basically ensures 
the entire DNA content from the sample is available in the solution and can be 
measured correctly. However, this step was excluded for the ease of performing the 
assay and to maintain the integrity of the cells following the viability test. The drug 
panel had bortezomib and mitoxantrone HCl that are cytotoxic drugs, when treated 
with them the cells were lysed thereby releasing the DNA into the media. As a result 
the readings of these treatments were much higher than the baseline reading observed 
when the cells were not lysed. Another explanation could be that these drugs caused 
an increase in the number of cells but a reduction in metabolic activity. While this 
could be possible, it does not seem to correlate with the images that clearly indicate 
initiation of senescence. Another important factor which supported the use of 
PrestoBlue is the ability to obtain accurate measurement of viability using either 
fluorescence or absorbance readings in contrast the PicoGreen reagent require only 
plate fluorescence readings to get accurate results. In order to obtain fluorescence 
readings, an additional step to the screen would be required. This would involve 
transferring the media into a black 96-well plate in order to get the accurate 
fluorescence readings, as black ImageLock plates (essential for the IncuCyte wound 
scratch assay) are not available. Taking these factors into account, particularly the 
accuracy of the assay, PrestoBlue was selected as the preferred cell viability assay to 
be incorporated into the primary screen.  
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The third parameter to be assessed is the change in the mesenchymal properties of 
the PC-3
VimRFP 
reporter cells. As mentioned earlier, these cells have been created by 
manipulating the PC-3 cells to express RFP under the influence of the vimentin 
promoter region. These cells report changes in vimentin expression driven by the 
promoter region in the form of RFP intensity. The IncuCyte
TM
 control software has a 
metric that measures the RFP intensity in a given well, this metric can be 
incorporated to assess the corresponding changes in the vimentin expression. The 
RFP intensity per well was measured following a wound scratch migration assay that 
was performed in the presence of 4 drugs, rapamycin, simvastatin, vorinostat and 
maprotilline. The wound scratch images in Figure 17A show that simvastatin, 
vorinostat and maprotilline inhibit migration whereas rapamycin shows an almost 
90% wound closure. Based on this we hoped to observe a reduction in RFP intensity 
when treated with simvastatin, vorinostat and maprotilline and a baseline RFP 
intensity value similar to the negative control for rapamycin. However, as shown in 
Figure 17B, simvastatin showed the highest RFP expression followed by vorinostat, 
maprotilline and rapamycin. But it is important to note that a protein like vimentin is 
governed by numerous factors at both a transcriptional and post-transcriptional level 
one of which includes the promoter region. Some other factors include cis-regulatory 
elements near the promoter that interact to enhance transcription (Pieper et al. 1992). 
Therefore, the reporter activity will not necessarily reflect vimentin protein levels nor 
will it encompass all the factors that modulate the endogenous transcriptional 
vimentin expression. In order to validate the results, an experiment was performed to 
compare the vimentin expression levels obtained by the IncuCyte
TM
 control software, 
FACS and qRT-PCR. While IncuCyte
TM
 control software measures the overall RFP 
intensity in each well of a 96-well plate, FACS measures the RFP intensity of every 
individual cell and qRT-PCR on the other hand measures the total, endogenous 
vimentin mRNA levels. As observed in Figure 19, the results obtained from all three 
experiments are different for the indicated treatments and show no particular pattern. 
Essentially the IncuCyte
TM
 control software, FACS and qRT-PCR show different 
measurements of vimentin expression. While each method is accurate for what they 
are designed to measure, they are not correlated nor were there any discernable 
patterns that can show a relation between inhibition of migration and vimentin 
reporter expression. This experiment was not replicated due to time limitations, as a 
result, while the RFP expression from the IncuCyte ZOOM will be measured during 
the primary assay, this measure will not be a used a criteria for the identification of 
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hits. Repeating this experiment and using high-content imaging technique as an 
alternative to measure and further verify this data will be useful to determine the role 
of the reporter, however this could not be carried out in the duration of this project. 
Another alternative could be to observe RFP-vimentin expression at previous time 
points while the cells are still migrating as opposed to the last time point when they 
have filled the wound about 90% which could result in reduced expression of 
vimentin. 
As an alternative to measure the RFP expression, vimentin protein expression was 
assessed as an alternative to transcriptional monitoring of changes in the 
mesenchymal phenotype. Considering the high-throughput nature of the assay, we 
opted for an InCell Western
TM
 assay that is usually performed in a microplate 
(including a 96-well plate) format and can be used to determine the protein 
expression of a target protein (i.e. vimentin) in intact cells. As demonstrated in 
Figure 20, no significant changes in vimentin protein expression when treated with 
33 drug treatments from the library as a part of a pilot study. One explanation for this 
phenomenon is that PC-3 cells express very high levels of vimentin, which is a very 
stable protein with slow turnover kinetics (Singh et al. 2003). As the assay is 
performed over a relatively short time frame of 24 hours, this may not be sufficient 
time to observe changes in the translational or protein level of vimentin. As a result, 
the InCell Western
TM
 assay will not form part of the primary screening assay to 
assess vimentin expression. 
Based on all of the data obtained in this study, a primary screening assay has been 
developed to measure three parameters over two steps. The first step is to perform 
the wound scratch migration assay, where the IncuCyte ZOOM system will be used 
to measure the migration and RFP intensity of PC-3
VimRFP 
cells (not to be used as a 
criteria in identifying shortlisted candidates), followed by a second step to measure 
cell viability using the PrestoBlue reagent. One of the most important factors to be 
determined for a high throughput screen is the reliability and reproducibility of the 
screen. The Z’ factor is a statistical tool to measure the reliability and reproducibility 
of a given high-throughput screen. It measures the separation between the negative 
and the positive control. The Z’ factor was calculated for 2 x 96-well plates that 
underwent a pilot study using the formula mentioned in chapter 2.9 for the migration 
data obtained. The plates showed a Z’ factor higher than 0.5 (Table 7). The other 
parameters were not used to calculate the Z’ Factor as the quality and reliability of 
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the assay relied heavily on migration as a parameter than the others. The differences 
in the Z’ factor values between the two plates could be as a result of manual or 
technical errors as it was the first pilot test run of the primary screening assay. A Z’ 
factor higher than 0.5 represents an assay of good quality and reliability. Based on 
this, I have confidence that the primary screen I have developed is of good quality, 
reliability and reproducibility for subsequent drug screening applications. In the 
following chapter this primary screen will be used to identify potential candidates 
from a library of 420 drugs that can inhibit the migration and invasion of the 
metastatic PC-3 PCa cell model. 
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Chapter 4: Performing the Multi-Parameter 
Primary Screen 
4.1 Introduction 
In the previous chapter we have outlined the optimization process for a variety of 
factors essential for the establishment of an effective screening assay. This has 
allowed us to determine the final parameters to be assessed during the multi-
parameter primary screening assay using the FDA-approved drug library. 
Cytochalasin D and DMSO were selected as the positive (inhibitory) control and the 
negative (vehicle) control respectively. Wound scratch migration, viability and 
vimentin-RFP expression were finalised as the parameters to be investigated as a part 
of the screen. A pilot version of the screen was performed to assess the ease of 
performing the proposed screen as well as the quality and reproducibility of the 
assay. On receiving satisfactory results, the format used during the pilot screen was 
finalized as the format for the primary screen. The primary screen format was set to 
be as follows: 
 Wound scratch migration (relative wound density) and vimentin RFP 
expression assessed using the IncuCyte ZOOM system  
 Cell viability assessed using the PrestoBlue assay  
Chapter 4 outlines the data extracted from the primary screen that was executed for 
all 420 drugs from the FDA approved library. The variation between replicates and 
different screens was taken into account prior to analysis. The shortlisted drugs were 
then classified into the different selection criteria classes, whereby lead candidates 
were selected for further study. 
4.2 Materials and Methods 
The common materials and methods have been outlined in chapter 3. Any additions 
and alterations to the materials and methods specific to this chapter are outlined 
below.  
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4.2.1 High-throughput multi-parameter primary screen 
As mentioned in the previous chapter, a multi-parameter primary screen has been 
developed to assess cell migration, vimentin-RFP expression and cell viability. This 
is achieved by following a two-step process; performing a wound scratch migration 
assay using the IncuCyte ZOOM system followed by a cell viability test using the 
PrestoBlue reagent. The assays are outlined in detail in 2.5 and chapter 2.6 
respectively. 
4.2.2 Plate Layout 
96-well ImageLock
TM
 plates were used to perform the screen. Duplicates of 33 drug 
treatments followed by an appropriate number of positive control (x12 wells), 
negative control (x12 wells) and blank (x4 wells) were randomised across each plate. 
An example of the plate layout can be seen in Figure 21. Three biological replicates 
of each plate were assessed and the drugs were randomly positioned in each plate 
replicate. The IncuCyte ZOOM system can accommodate 6 plates at one time; 
therefore, 66 drugs were screened together. A total of 36 plates, including biological 
replicates, were required to screen all 420 drugs.  
 
Figure 21 Example of the plate layout used for the primary assay  
Duplicates of each drug along with an appropriate number of positive control, negative control and 
blank. 
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4.3 Results 
Prior to analysing the results obtained from the primary screening assay, it is 
essential to assess some quality control parameters such as the degree of variation 
between the plates and the Z’ factor values. These parameters will help determine the 
reliability and quality of the data.  
4.3.1 Interplate variability 
Following the completion of the primary screen it was important to assess the degree 
of variation amongst the migration data for the 36 individual plates that comprised 
the primary screen. The identification of significant variations in the wound density 
values of the negative and positive control across the plates could imply irregularities 
in the corresponding wound density values of the 33 drug treatments on that plate. Z-
scores were used to assess this variability. The DMSO values on each plate were 
averaged (standard deviation was less than 1%). Based on the z-score formula, the 
mean of DMSO values across all plates (µ) and their standard deviation (σ) was used 
to calculate the DMSO z-score for each plate. Similarly the z-score values for 
cytochalasin D treatments were calculated for each plate and both are displayed in 
Figure 22. The DMSO z-scores for plates 3 and 9 that are highlighted in red show 
significant variation, whereas the cytochalasin D z-scores do not show significant 
variation for any of the plates (refer to Table 6 for variation criteria). Due to 
significant variation in plates 3 and 9, the relative wound density for DMSO and the 
blank or no drug treatments were assessed and it was observed that the relative 
wound density was lower by more than 10% when compared to the average wound 
closure for the negative and blank controls. As a result, they were excluded from 
further analysis, leaving 34 plates for data analysis. 
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Figure 22 Assessing the interplate variability amongst the 36 plates 
(A) The mean z-score of DMSO treatments for individual 36 plates are compared. Highlighted in red, 
plate3 and plate 9 show significant variation (p < 0.01). (B) The mean z-score of cytochalasin D 
treatments for individual 36 plates are compared and none of the plates show a significant variation. 
This shows that amongst 36 plates, two plates show variable DMSO relative wound density whereas 
no plate shows variation in cytochalasin D relative wound density data. For each plate, n=6 technical 
replicates, the error bars are in the range of 10
14
 and hence not shown in the graph.  
  
A 
B 
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4.3.2 Assay quality 
Similar to the analysis performed in chapter 3, the assay quality was determined for 
all plates that underwent the primary screen. The Z’ factor for individual plates as 
well as the overall Z’ factor across all 34 plates was calculated. All the plates had a 
Z’ factor value higher than 0.5, barring three plates as highlighted in Table 8 (plates 
12, 13 and 17 indicated in red text). The overall Z’ factor was calculated using the 
mean of the controls across all 34 plates and is important in terms of assessing the 
assay quality. The overall Z’ factor value of the assay was found to be 0.58. It should 
be noted that scores between 0.5 - 1.0 indicate an excellent assay (Zhang et al. 1999).  
Table 8 Z’ factor across all 34 plates that underwent the primary screen 
Plate Number Z’ factor 
1 0.905112 
2 0.815261 
4 0.78761 
5 0.57961 
6 0.755255 
7 0.837922 
8 0.648459 
10 0.741331 
11 0.695029 
12 0.281696 
13 0.442215 
14 0.622274 
15 0.691802 
16 0.729458 
17 0.497181 
18 0.649053 
19 0.736976 
20 0.515226 
21 0.760768 
22 0.632688 
23 0.801182 
 66 Chapter 4: Performing the Multi-Parameter Primary Screen 
 
24 0.642689 
25 0.718251 
26 0.635977 
27 0.888404 
28 0.765092 
29 0.828396 
30 0.885096 
31 0.663430 
32 0.873581 
33 0.874164 
34 0.890510 
35 0.825475 
36 0.797287 
4.3.3 Screening 420 drugs using the high-throughput multi-parameter primary screen 
The primary screen provided three sets of data; the relative wound density as a 
measure of migration, RFP intensity as a measure of the vimentin reporter and the 
conversion of resazurin to rezarin as a measure of cell viability data in response to 
each drug. The migration, vimentin-RFP expression and viability data for all 420 
drugs was converted to z-scores for the ease of comparing and identifying hits. These 
results have been represented as scatter plots for each parameter (Figure 23, Figure 
24 and Figure 25). Each point represents the mean z-score for one drug treatment. 
Drugs with negative z-scores indicate a reduction or an inhibition of the specified 
parameter whereas the drugs with positive z-scores demonstrate an increase of the 
indicated parameter. The critical z-scores and their corresponding confidence levels 
have been mentioned in Table 6. Z-score values higher than 1.6 can be used to 
identify treatments significantly increasing (positive value) or significantly inhibiting 
(negative value) for a given parameter. The confidence interval and p-value for 
commonly assessed z-score values are mentioned in Table 6. Based on the z-score 
values for the migration and viability parameters, the shortlisted drugs were 
classified into different categories as mentioned in the next section. 
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Figure 23 Migration Z-scores  
Each point represents the wound density z-score of a drug treatment on the x-axis (excluding 
controls). The drugs with z-scores between -1.6 and -2 are identified hits with 90% confidence while 
those with z-scores beyond -2 are identified as hits with 95% confidence. No treatment shows a 
positive z-score greater than 1.6 (n=3 biological replicates for each treatment as defined in chapter 
2.9). 
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Figure 24 Viability Z-Scores 
Each point represents the viability z-score of a drug treatment on the x-axis (excluding controls). The 
drugs with z-scores higher than 1.6 on the negative side of the Y-axis are identified as low viability 
hits whereas z-scores greater than 1.6 on the positive side show increased viability (n=3 biological 
replicates for each treatment as defined in chapter 2.9). 
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Figure 25 Vimentin-RFP Z-scores 
Each point represents the viability z-score of a drug treatment on the x-axis (excluding controls). The 
points that lie beyond the orange line represent drugs with a significant change in the RFP expression. 
Most treatments show a significant increase in the RFP expression (n=3 biological replicates for each 
treatment as defined in chapter 2.9).  
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4.3.4 Selection criteria for identifying hits from the primary screen 
With the help of z-scores, the different criteria for determining hits were finalised. 
The drugs were classified into two categories based on migration inhibition, high 
confidence drugs with 95% confidence and medium confidence drugs with 90% 
confidence. Any of these drugs that showed a significant reduction in viability were 
classified as cytotoxic drugs. Table 9 represents the different selection criteria for 
identifying hits. As mentioned in the previous chapter, the results obtained from the 
IncuCyte
TM
 control software regarding the changes in the vimentin-RFP expression 
have not been used as a selective parameter to determine potential hits from the 
screen. 
Table 9 Selection criteria 
4.3.5 Identifying hits from the multi-parameter primary screen 
With reference of the selection criteria provided in the previous section, 39 drugs 
were identified as hits from the primary screen. A list of the high confidence and 
medium confidence candidates is represented in Table 10 with drugs that inhibited 
cell viability highlighted in red. The z-scores of these potential candidates are 
represented in Figure 26A; and the relative wound density of the candidates can be 
viewed in Figure 26B. As per the selection criteria, 28 drugs were identified as high 
confidence drugs, 11 drugs were classified as medium confidence drugs and amongst 
them 17 drugs showed reduced cell viability. Most of the drugs have a relative 
wound density lower than 75%. This observation could be useful in setting up a 
migration benchmark for future validation assays. One can note that there are some 
medium confidence drugs that have a lower wound density than some high 
confidence drugs. This can be explained by the fact that z-scores are measured for 
individual plates and the mean/standard deviation calculated for each plate varies 
based on the treatments present on that plate. For example, if there are more 
migration inhibiting candidates on one plate, the z-score for a given inhibition would 
Criteria Observation 
High Confidence Wound density and vimentin expression has a z-scores ≤-1.96 
Medium confidence 
Wound density and vimentin expression has a z-scores 
between -1.645 and -1.96 
Cytotoxic Cell viability z-score ≤-1.645 (viability less than 80%) 
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be lower than on a plate where there are less inhibiting candidates where the z-score 
will be relatively high for an inhibiting candidate. The viability relative to DMSO 
has been represented in Figure 26C. As mentioned in the selection criteria, any 
drugs with viability less than 80% can be considered cytotoxic. Almost 50% 
candidates seem to have reduced the cell viability significantly (Table 10). 
 
Table 10 Potential candidates identified from the primary screen 
High Confidence Drugs Medium Confidence drugs 
Ethinyl estradiol Vorinostat Simvastatin 
Nitozoxanide Doxorubicin Fluvastatin 
Disulfiram Elvitegravir Sorafenib 
Albendazole Paclitaxel Fenbendazole 
Toremifene citrate Pimobendan Topotecan 
Itraconazole BIBR1048 Vincristine 
Mitoxantrone HCl Artemether Floxuridine 
Bortezomib Docetaxel Teniposide 
Dasatinib Idarubicin Chlorprothixene 
Zactima Maprotilline Mianserin 
Sonazine Clomipramine Asenapine 
Irinotecan Clomifene Tamoxifen citrate 
2methoxyestradiol Apatinib  
Epirubicin   
Drugs highlighted in red represent cytotoxic candidates  
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Figure 26 Migration and viability data of potential candidates identified from the primary screening 
assay  
Potential candidates identified from the primary screening assay were categorised into high 
confidence and medium confidence categories as well as cytotoxic candidates. (A) The relative wound 
density of the candidates are shown, majority of the drugs have a wound density lower than 75% 
(dotted line) (B) The viability data made relative to the negative control are shown, drugs with 
viability lower than 80% were considered cytotoxic. Almost 50% drugs have reduced cell viability (C) 
The z-scores calculated for the migration and viability data of the high confidence and medium 
confidence drugs are compared. The high confidence drugs are represented as plain bars whereas the 
medium confidence drugs are represented as hatched bars. The cytotoxic candidates show a viability z 
scores below the orange line (i.e. z-score < 1.645). The z-score selection criteria is mentioned in Table 
9 (n=3 biological replicate for each treatment as defined in chapter 2.9; error bars represent ±SD; error 
bars for figure 26 (C) are too small (10
14
 range) hence not plotted in the graph).  
B 
A 
C 
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Some drugs such as ethinyl estradiol, bortezomib, dasatinib, elvitegravir proved to be 
cytotoxic for the cells, while some drugs changed the cell morphology following a 
24-hour treatment such as vorinostat, irinotecan, sorafenib.  Figure 27 shows wound 
scratch images of the controls as well as some examples of the cytotoxic candidates. 
Almost 100% wound closure is observed when treated with the negative vehicle 
control DMSO whereas negligible wound closure is observed in the presence the 
positive control cytochalasin D over a period of 24 hours (Figure 27A). Figure 27B 
shows images of bortezomib, elvitegravir and ethinyl estradiol, drugs that have 
significantly reduced cell viability. The images show the different cell morphologies 
when subjected to such toxic treatments for a period of 24 hours. Figure 28A 
represents some treatments that inhibit migration and cause changes in the cell 
morphology. Vorinostat and sorafenib make the PC-3VimRFP cells elongated and 
spindly whereas irinotecan causes the cells to stretch out like tiles. Figure 28B shows 
images of zactima, disulfiram and tamoxifen citrate that inhibit migration without 
any change in viability or morphology. 
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Figure 27 Wound scratch images of controls and cytotoxic candidates identified from the primary 
screening assay 
The scale represents 300 µm. (A) DMSO shows almost 100% closure whereas cytochalasin D shows 
almost 0% closure without affecting cell morphology or viability. (B) Inhibition of cell migration 
(wound closure) as a result of reduced viability. On closer inspection one can observe the morphology 
of the severely stressed cells at the 24-hour time point. Bortezomib and ethinyl estradiol causes the 
cells to round up and detach. On the other hand Elvitegravir does not severely show an elongated/ 
spindly morphology but still shows a reduction in viability.  
B 
A 
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Figure 28 Wound Scratch images of potential candidates identified from the primary screening assay 
The scale represents 300 µm. (A) The indicated drugs caused inhibition of migration (wound closure) 
along with a change in cell morphology. Vorinostat and sorafenib resulted in spindly, elongated cells 
at the 24-hour time point whereas irinotecan showed flattened, stretched out cells. (B) The indicated 
drugs have inhibited migration (wound closure) without affecting any other cell characteristics such as 
cell morphology or viability (10x magnification).  
A 
B 
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4.4 Discussion 
The cell-based multi-parameter primary screen we successfully developed was used 
to screen 420 drugs from the FDA-approved drug library to identify potential 
candidates that can inhibit the migratory and invasive properties of the metastatic 
PC-3 cell lines. On completion of the assay it was important to assess the degree of 
variation amongst all plates involved in the primary screen. For this purpose, the 
mean z-scores of each plate treated with DMSO, the negative (vehicle) control and 
cytochalasin D, the positive control were calculated and compared. As observed in 
Figure 22, all cytochalasin D z-scores and majority of the DMSO z-scores were 
within range (not greater than 2 or less than -2) barring plates 3 and 9. Each of these 
plates had a DMSO z-score values higher than 2 indicating a very high variation. For 
this reason, we assessed the relative wound density values for DMSO as well as the 
blank (no drug or DMSO treatment) and it was found to be around 74% for both 
plates, which is lower by 10% than the average value of 85%. A reduction in cell 
migration even without the presence of any compound could also influence the 
migration data for other treatments on that plate. As a result, the data obtained from 
these plates was excluded from further analysis.  
With the help of the statistical tool Z’ factor we have provided data that the assay 
developed is reliable, reproducible and accurate. The Z’ factor determines the 
separation band between the positive and the negative controls of an assay. A Z’ 
factor value greater than or equal to 0.5, represents a separation band of about 15 
standard deviations between the values of the positive and negative controls. It 
should be noted that plates 12, 13 and 17 have values lower than 0.5. While assays 
with Z’ factors lower than 0 represent overlapping positive and negative controls, 
values greater than 0 but lesser than 0.5 represent assays with a separation degree 
lesser than 15 standard deviations but greater than 0. While this reduces the quality 
of the assay slightly, plates 12, 13 and 17 are still reliable screens. Therefore, they 
were not excluded from further analysis.  
Z-scores were calculated for all drug responses extracted from the wound scratch 
assay using the IncuCyte
TM
 ZOOM system as well as the data measured by the 
PrestoBlue cell viability test. For the ease of comparing and identifying hits, 
migration, viability and RFP expression data was represented as scatter plots that 
have been shown in Figure 23, Figure 24 and Figure 25. Drugs that significantly 
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inhibited cell migration with or without affecting cell viability were considered to be 
hits. As mentioned in the previous chapter, the data from IncuCyte RFP expression 
will not be used to identify the hits from the assay but was simply measured to 
observe changes in the reporter expression. The data from the screen provides us 
with various categories of results apart from those inhibiting migration. Some of the 
candidates significantly reduced cell viability without affecting cell migration 
whereas there are some candidates with increased cell viability, and some drugs 
brought about changes in cell morphology following drug treatments as noted in the 
wound scratch images. By looking at the migration data from earlier time points we 
could also identify candidates that increase migration. Whilst outside the scope of the 
current project, these candidates will be investigated as a part of the future studies 
emanating from this work (as outlined in chapter 6).  
Almost 40 drugs have been shortlisted from the screen as mentioned in Table 10 
based on their ability to inhibit the migratory properties of the PC-3
VimRFP
 cells. It is 
noteworthy that almost half of the potential hits identified show cytotoxicity or 
highly reduced viability. This can be confirmed in the Figure 26A that shows the z-
scores and the corresponding viability values made relative to DMSO of the potential 
candidates. One hypothesis for this observation could be the use of 10μM as the drug 
concentration for the primary screen. The drug concentrations usually lie in the μM 
range when used in drug screening assays (Lipinski et al. 2012). While 10μM is a 
standard concentration for screening assays (within the μM range), it is much higher 
than the IC50 values of most drugs. The concentration was selected for the ease of 
performing the screen at a single concentration and to ensure that weakly positive 
candidates that might require high concentrations to discern the desired effect of 
migration inhibition were not lost in the screen. A dose response study will be 
performed to identify the cytotoxic candidates that can inhibit migration at lower 
drug concentrations. Figure 26B shows the relative wound density values of all the 
potential candidates. It can be observed that majority of the drugs show a wound 
density lower than 75%. This value can be set up as a benchmark for migration 
inhibition in further validation assays.  
As mentioned in chapter 2.4, the drug library comprises of drugs that belong to a 
wide range of fields including oncology, inflammation, treatments of various 
microbial and parasitic infections as well as antipsychotic drugs. Consequently the 
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drugs identified by the screen belong to diverse fields. Some drugs that reduce the 
cell viability or promote cell death like bortezomib, dasatinib, docetaxel, 
mitoxantrone hydrochloride and paclitaxel are known cytotoxic drugs that are being 
used in the treatments of various cancers like myeloma, lymphoma, leukaemia, 
breast cancer and even prostate cancer (Picot et al. 2011; Foà et al. 2011; Gilbert et 
al. 2005). While the anti-cancer drugs proved to be the most obvious hits from the 
screen, there are drugs like albendazole, nitazoxanide, fenbendazole, elvitegravir that 
reduced cell viability in the assay but are not yet involved in any cancer treatments. 
These drugs are used in the treatment of protozoal, helmentic and HIV infections 
(Horton 2000; McLeod et al. 2014; Pandey 2014). These cytotoxic candidates will be 
discussed in detail in chapter 6 as a part of the future directions emanating from this 
study.  
Other known anti-cancer drugs that have been identified include topotecan, 
irinotecan, epirubicin, doxorubicin, idarubicin, 2-methoxyetradiol and vincristine. 
They did not reduce cell viability significantly but some of the images showed signs 
of cell stress. Topotecan and irinotecan belong to a class of drugs derived from 
camptothecin, a natural occurring compound that is a type I topoisomerase inhibitor 
(Pommier 2006). While topotecan has been involved in clinical trials as a treatment 
for CRPC, it showed limited anti-tumour activity along with increased accounts of 
granulocytopenia, a marked reduction in white blood cells (Hudes et al. 1995). 
However, it has been successfully used for the treatment of small-cell lung 
carcinoma (von Pawel et al. 1999). Irinotecan on the other hand has been used in the 
treatment of colorectal cancer (Rothenberg et al. 1996). Epirubicin, doxorubicin and 
idarubicin belong to an antitumour group of drugs called anthracyclines. Epirubicin 
and doxorubicin have been used in palliative treatment of CRPC but they present 
severe toxicity (Petrioli et al. 2008). However, epirubicin shows reduced levels of 
cardiotoxicity (Cortés-funes et al. 2007). A natural metabolite of estradiol, 2-
methoxyestradiol shows antiangiogenic properties and has undergone phase I clinical 
trials towards the treatment of breast cancer and another phase II clinical trials for the 
treatment of CRPC (Lakhani et al. 2003). Vincristine is a plant based alkylating 
agent that intercalates with the DNA to cause cell death. It has been widely used in 
the treatment of lymphomas and leukaemia (AusDI 2013). Phase II clinical studies 
have been carried out for a combination of oral cyclophosphamide (an alkylating 
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agent), oral low-dose dexamethasone (a corticosteroid, anti-inflammatory agent) and 
intravenous vincristine. It was found that this concoction of drugs was well tolerated 
and could be used as an alternative therapy for patients with several comorbidities 
and high risk for treatment related toxicity (Trump 2003).  
Some anti-cancer drugs like teniposide, zactima sorafenib and floxuridine, did not 
reduce the cell viability significantly. Most of these drugs are have been pursued as 
alternate or combination treatments for the treatment of various stages in prostate 
cancer but have not been very useful clinically. Teniposide is another type II 
topoisomerase inhibitor that is known to induce nuclear DNA degradation (Tepper et 
al. 1992). However, its use in PCa therapy has not been studied. Zactima or better 
known as vandetanib is a kinase inhibitor and is used in the treatment of thyroid 
cancer (Sim et al. 2014). Zactima is undergoing a clinical study to be used as a 
treatment for metastatic CRPC before the use of docetaxel. It is also undergoing a 
study that involves combination therapy between zactima and bicalutamide, a non-
steroidal anti-androgen drug (Mukherji et al. 2013). Sorafenib is also a kinase 
inhibitor that is used to treat renal cell carcinoma as well as hepatocellular carcinoma 
that cannot undergo surgery (Rini 2006). Sorafenib has undergone phase II clinical 
trials for the treatment of metastatic CRPC as well as androgen independent PCa. 
While it showed moderate activity as a second line treatment for CRPC (Aragon-
Ching et al. 2009), it showed some promising result for androgen independent PCa 
(Dahut et al. 2008). Floxuridine on the other hand belongs to a class of drugs called 
antimetabolites. It is commonly used in the treatment of colorectal cancer or cancer 
of the gastric tract (Li et al. 2014). A phase II clinical study toward the circadian 
infusion of floxuridine as a treatment for CRPC was carried out in 1998, however the 
outcomes were insufficient to pursue the study further (Rajagopalan et al. 1998).  
Another category of drugs that have been identified by the assay is synthetic versions 
of estrogen or estradiols as well as estrogen receptor modulators. These include drugs 
include 2methoxyestradiol, ethinyl etradiol, tamoxifen citrate, toremifene citrate, 
clomifene. While ethinyl estradiol caused a significant reduction in cell viability, the 
others did not seem to affect cell viability at all. Ethinyl estradiol has been used as an 
androgen suppressor in PCa treatment and is currently undergoing trials to target 
CRPC (Izumi et al. 2010). Toremifene citrate on the other hand is being used in the 
treatment of breast cancer and is undergoing clinical trials to see if it can prevent the 
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establishment of PCa in men having high levels of prostatic intraepithelial neoplasia 
(PIN) and well as the treatments of various side effects caused by ADT (GTx 2005). 
Tamoxifen citrate is currently being used as an androgen deprivation treatment for 
advanced adenocarcinoma of the prostate (Castle 2008).  
Several antidepressants and antipsychotic drugs were also identified from the 
primary screen, namely, asenapine, mianserin, maprotilline, sonazine and 
clomipramine. Asenapine is used in the treatment of schizophrenia and acute mania 
associated with bipolar disorders (Weber et al. 2009). Maprotilline and mianserin are 
commonly used as antidepressants (Möller et al. 1991). Sonazine blocks the 
dopamine receptor and is used as an antipsychotic for various disorders (Baumeister 
2013). Neither of these drugs has been known to affect the migration or proliferation 
of PCa cells in the past.  
Simvastatin and fluvastatin belong to a group of drugs called statins that are known 
to reduce plasma cholesterol levels and prevent cardiovascular diseases (Sugerman et 
al. 2013). Statins have showed that they can reduce the risk as well as the growth of 
several cancers like renal cell carcinoma, breast and melanoma (Fang et al. 2013; 
Demierre et al. 2005). Several studies mentioned in the review by Murtola et al. 
(2008) suggest that statins may play a role in the apoptosis of several PCa cell lines 
as well as the prevention of PCa establishment. However, further clinical studies 
need to be performed to back up the use of statins as a preventive therapy (Murtola et 
al. 2008).  
Vorinistat or SAHA is a well-known histone deacetylase (HDAC) inhibitor. It has 
been commonly used in the treatment of cutaneous T-cell lymphoma (Demierre et al. 
2005). It has undergone clinical trials for the treatment of CRPC, however one study 
concluded significant toxicity in patients after the use of vorinostat but warrants 
further investigation (Bradley et al. 2009). Some studies have shown the importance 
of HDAC inhibitors in inhibiting or suppressing EMT (Yoshikawa et al. 2007). 
However, there have been contradicting studies like that of Kong et al that claim 
HDAC inhibitors promote EMT (Kong et al. 2012). These contrasting views on 
HDAC inhibitors have developed a special interest in observing the effects of 
vorinostat on migration inhibition with the further validation studies.  
Artemether is an antimalarial agent (Tayade et al. 2010) whereas BIBR1048 is a 
thrombin inhibitor (Gustafsson 2003) and Pimobendan is commonly used to treat 
 82 Chapter 4: Performing the Multi-Parameter Primary Screen 
heart failures in canines (Boyle et al. 2012). Most of the drugs involved in PCa 
treatments are being used as chemotherapeutic agents or ADT agents following the 
spread of the disease. With the help of this screen, we aim to identify drugs that may 
be used as a preventive measure post diagnosis in high risk disease patients and 
prevent the progression of the disease to a lethal stage. The drug can also be used in 
conjunction with current therapies as a neoadjuvant or adjuvant agent or as an anti-
metastatic agent. Several speculations about how to use the selected drug can be 
made, however, the exact use and the timeline of the therapy can only be determined 
after a drug has been shortlisted. The potential drug candidates will undergo a series 
of validation assays to filter the existing hits and identify the most potent drug(s).  
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Chapter 5: Performing Validation Studies 
on Candidates Identified from 
the Primary Screen 
5.1 Introduction 
The FDA approved drug library was successfully screened using the cell-based 
multi-parameter primary screening assay. Thirty-nine drugs that belong to various 
fields have been shortlisted from the library. A detailed discussion regarding their 
mode of action and existing relation to PCa treatments have been mentioned in the 
previous chapter. Following the primary screen, a series of assays were performed to 
validate the results obtained. Dose response studies were performed to identify the 
lowest concentration of the drug candidate that can be used to inhibit migration. 
These concentrations will then be utilised to execute further validation studies. 
Performing a wound scratch migration assay in an alternative PCa cell line such as 
DU145 as well as performing a wound scratch invasion assay comprised some of the 
validation assays outlined in this chapter. Based on the results of these assays, the 
most potent candidate(s) were identified amongst the primary screening hits.  
5.2 Materials and Methods 
The common materials and methods have been outlined in chapter 3. Any additions 
and alterations to the materials and methods specific to this chapter are outlined 
below. 
5.2.1 Materials 
Matrigel
TM 
was purchased from B.D. Biosciences.  
5.2.2 Cell Lines 
PC-3
VimRFP 
cells will be used for further validation studies along with the parental 
PC-3, DU145 and LNCaP cells. LNCaPs represent an AR+ androgen-responsive cell 
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model of PCa, and are only weakly metastatic in vivo (van Steenbrugge et al. 1991). 
LNCaPs use the same cell culture conditions as mentioned in chapter 2.1  
5.2.3 Wound Scratch Migration Assay 
The wound scratch migration assay methodology has been outlined in chapter 2.5. 
For DU145 migration assays, the cells were seeded at a density of 15,000 cells/well. 
5.2.4 Wound Scratch Invasion Assay 
Matrigel
TM 
is
 
a biomatrix commonly used to represent the extracellular matrix in 
vitro. Prior to use, Matrigel
TM
 is thawed on ice at 4°C overnight. A 96-well 
ImageLock plate is layered with 50μl MatrigelTM at a concentration of 100μg/ml and 
left in the incubator overnight. The next day, any remnants of liquid Matrigel
TM
 are 
aspirated and PC-3
VimRFP
 cells are seeded at a concentration of 20,000 cells/well. The 
cells are again left to form a confluent monolayer overnight. A uniform wound is 
created with the help of the WoundMaker
TM
 as mentioned in 2.5. Once the wound 
has been successfully created, the wells are washed with fresh media at least twice. 
Following which the media is aspirated and 50μl MatrigelTM at a concentration of 
1mg/ml is added to each well. The plate is then left in the incubator for 1 hour to 
allow the solidification of Matrigel
TM. Following which 100μl of fresh media is 
added to the wells and the plate is placed into the IncuCyte ZOOM. A scan is set up 
every 3 hours to measure wound density over a period of 48 hours.  
5.3 Results 
5.3.1 Dose Response Studies 
Dose response studies were performed for all 39 drugs that were identified by the 
primary assay. The objective of this study were 1) aid validation of the primary 
screen results by repeating the assay (10μM dose); 2) identify the lowest drug 
concentration that can effectively inhibit migration; and 3) reduce cell viability 
effects of cytotoxic drugs to clarify their effect on cell migration. The dose response 
studies were carried out using PC-3
VimRFP
 cells. A wound scratch migration assay 
followed by PrestoBlue cell viability test was performed for this purpose.   
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Initially the studies were performed using drug concentrations ranging from 10μM to 
0.1nM (1 in 10 serial dilutions). However, an immediate drop in migration inhibition 
was observed between the concentrations of 10μM and 1μM whereby very few drugs 
were observed to inhibit migration at concentrations lower than 10nM as observed in 
Figure 29. Following this observation, the dose response studies were repeated at the 
following concentrations 30μM, 10μM, 3μM, 1μM, 0.1μM and 10nM. Relative 
wound density that was less than 6 standard deviation values of the negative control 
(equating to less than 73% relative wound density), were selected as the optimal 
inhibitory concentration. Drug concentrations that retained viability ≥ 80% relative 
to the negative (vehicle) control were considered not to effect cell viability (i.e. non-
cytotoxic). The lowest concentration that met both these conditions was selected as 
the optimal concentration for subsequent validation assays. The dose response 
studies for mitoxantrone HCl have been represented in Figure 30. The concentration 
of 3μM fulfilled the condition of having a wound density less than 6 standard 
deviations of the negative control (dotted line) and cell viability greater than 80%. 
Therefore, 3μM was chosen to be the optimal concentration for mitoxantrone HCl. 
The wound scratch images of all 6 concentrations at the 0-hour and 24-hour time 
points are shown in Figure 31. Similarly the effective concentrations for all the 
potential candidates were identified. The migration and viability graphs of all the 
drugs are available in appendix B. 
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Figure 29 Examples from the first set of dose response studies performed for drug concentrations 
ranging from 0.1nM to 10µM  
Two examples from the first set of dose response studies are shown and the dotted line represents the 
inhibitory relative wound density benchmark (six standard deviations lower than the mean of the 
negative control). (A) The migration data for mitoxantrone HCl shows that there is a sudden loss of 
inhibition between 10μM and 1μM. Most of the drugs show a similar trend. (B) Vincristine is one of 
the few drugs that showed significant reduction even at 1nM. The error bars represent ±SD of n=4 
technical replicates for each treatment. 
 
 
  
A 
B 
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Figure 30 Dose response studies performed for mitoxantrone hydrochloride 
The error bars represent ±SD of n=3 biological replicates for each treatment. (A) The relative wound 
density of the indicated treatments as determined during the repeated dose response studies. The 
concentrations show a steady decrease in wound density with the increase in mitoxantrone HCl 
concentrations from 10nM to 30μM. (B) Similar to the migration data, there is a steady decrease in 
viability with the increase in mitoxantrone HCl concentration. Based on the selection criteria, the 3μM 
concentration relative wound density is less than the mean of the negative control by 6 standard 
deviations (dotted line) and shows viability greater than 80% (dotted line), it is therefore chosen to be 
the least potential concentration of mitoxantrone HCl.  
 
 
B 
A 
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Figure 31 Wound scratch images taken during the dose response studies for mitoxantrone HCl 
Mitoxantrone HCl is one of the potential candidates that underwent dose response studies. This figure 
shows the wound scratch images of the 6 different concentrations and their corresponding cell 
morphologies post 24-hour treatment. The scale represents 300 µm. There is a constant increase in 
wound closure with the decrease in drug concentration. The 30μM and 10μM concentrations cause 
cell stress and reduced viability as seen in the cell morphology image post the 24-hour treatment. 
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The optimal drug concentrations for the remaining 20 candidates were determined 
with the help of the criteria mentioned above and are outlined in Table 11 along with 
a list of candidates that were excluded from further analysis. All candidates showed 
the same extent of inhibition as seen in the primary screen. However, tamoxifen 
citrate was excluded from further studies, as it did not show the desired level of 
migration inhibition at the 10μM dose (Figure 32). The dose response data for 
tamoxifen citrate did not show significant wound closure (Figure 33). On the other 
hand, candidates such as ethinyl estradiol, nitazoxanide, irinotecan, topotecan, 
bortezomib, dasatinib, paclitaxel, floxuridine, albendazole, fenbendazole, epirubicin, 
doxorubicin, idarubicin, vorinostat were excluded as they did not show the desired 
level of migration inhibition without affecting cell viability. The dose response data 
for Topotecan is presented as an example (Figure 34). Wound closure inhibition was 
observed for higher doses (30μM-1μM) along with a significant reduction in viability 
(Figure 35). Similarly, the concentrations were calculated for other candidates.  
Table 11 Dose response study outcomes  
Drug  
candidate 
Optimal  
concentration 
(µM) 
 
Excluded drug  
candidate 
 
Reason for  
exclusion 
Disulfiram 10 Tamoxifen citrate Insufficient inhibition 
Mitoxantrone HCl 3 2methoxyestradiol Cytotoxic 
Toremifene citrate 10 Teniposide Cytotoxic 
Zactima 10 Ethinyl estradiol Cytotoxic 
Sonazine 3 Nitazoxanide Cytotoxic 
Elvitegravir 10 Irinotecan Cytotoxic 
Pimobendan 3 Topotecan Cytotoxic 
Artemether 3 Bortezomib Cytotoxic 
Clomipramine 3 Dasatinib Cytotoxic 
Clomifene 3 Paclitaxel Cytotoxic 
Apatinib 3 Docetaxel Cytotoxic 
Itraconazole 3 Vincristine Cytotoxic 
Asenapine 3 Floxuridine Cytotoxic 
BIBR1048 1 Albendazole Cytotoxic 
Maprotiline 3 Fenbendaxole Cytotoxic 
Mianserin 1 Epirubicin Cytotoxic 
Chlorprothixene 1 Doxorubicin Cytotoxic 
Sorafenib 3 Idarubicin Cytotoxic 
Simvastatin 1 Vorinostat Cytotoxic 
Fluvastatin 1   
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Figure 32 Tamoxifen citrate failed to inhibit migration while performing the dose response studies 
Tamoxifen citrate is one example of the candidates that showed insufficient inhibition following the 
dose response study. The error bars represent ±SD of n=3 biological replicates for each treatment. (A) 
The relative wound density for all treatments other than 30μM is greater than the inhibitory value 
(dotted line; 6SD lower than the mean of the negative control). (B) On the other hand, the viability 
determined for each concentration (except 30μM) is greater than 80% (dotted line). Tamoxifen citrate 
was found to inhibit migration in the primary screen (10μM) but failed to validate.  
  
A 
B 
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Figure 33 Wound scratch images taken during the dose response studies for tamoxifen citrate  
Tamoxifen citrate is one of the potential candidates that underwent dose response studies and was 
excluded owing to insufficient inhibition. This figure shows the wound scratch images of the 6 
different concentrations and their corresponding cell morphologies post the 24-hour treatment. The 
scale represents 300 µm. There is almost no change in wound closure after the 30μM concentration 
and no changes are observed in the cell morphology image post the 24-hour treatment. 
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Figure 34 Dose response studies performed for topotecan 
Topotecan is one of the cytotoxic candidates identified from the dose response studies. The error bars 
represent ±SD of n=3 biological replicates for each treatment. (A) The relative wound density for 
concentrations 1μM and higher is less than the inhibitory wound density (dotted line; 6 SD less than 
the mean of the negative conrol). (B) All the concentrations 1μM and higher show significantly 
reduced viability, less than 80% (dotted line). All the concentrations that show an inhibition in 
migration also reduce cell viability. 
  
A 
B 
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Figure 35 Wound scratch images taken during the dose response studies for topotecan 
Topotecan is one of the potential candidates that underwent dose response studies and was excluded 
due to increased cytotoxicity. This figure shows the wound scratch images of the 6 different 
concentrations and their corresponding cell morphologies post 24-hour treatment. The scale represents 
300 µm. There is a constant increase in wound closure with the decrease in drug concentration. The 
concentrations ranging from 30μM to 1μM show cell stress and reduced viability as seen in the cell 
morphology image post the 24-hour treatment. 
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5.3.2 Performing a wound scratch migration assay using the DU145 cell line 
After excluding the cytotoxic drugs, the 20 remaining drug candidates underwent 
wound scratch migration assays using DU145 cells as an alternate highly migratory 
and invasive PCa cell model. The wound scratch assay for DU145 cells has been 
optimized in the laboratory previously (Dr. Brett Hollier, personal communication). 
As in previous experiments this was combined with the PrestoBlue assay to monitor 
changes in DU145 cell viability.  
A relative wound density less than 6 standard deviations of the negative control 
value (equating to less than 73%) was considered to be an inhibitory treatment. 
Again viability less than 80% was considered to be cytotoxic. The relative wound 
density for the candidates and the viability data can be viewed in Figure 36. At the 
same time Z-scores were calculated for the migration and viability data of all the 
candidates to confirm the results obtained (Figure 37). Similar selection criteria as 
mentioned in Table 9 were considered for this assay. It was observed that 
mitoxantrone HCl and zactima showed the desired level of migration inhibition.  
However, these two drugs also showed a significant reduction in cell viability 
(Figure 38).   
5.3.3 Performing a wound scratch invasion assay for the potential candidates 
The tumour cells in vivo have to penetrate (invade) several tissue barriers such as the 
prostate ductal structures and basement membrane to enter the circulatory system. As 
invasion plays an important role in the metastatic cascade we determined the 
efficiency of the drug candidates in inhibiting invasion through Matrigel. For this 
purpose, the 20 potential candidates underwent a wound scratch invasion assay to 
monitor changes in the invasion profile of the PC-3
VimRFP
 cells. The cells have to 
invade a layer of matrigel
TM
 (mimics the basement membrane) in order to close the 
wound. The cells also underwent the PrestoBlue viability test to assess any changes 
in the viability profile after a 48-hour treatment. PC-3 cells usually show an 
approximate 50% wound closure after 48 hours when using a concentration of 
1mg/ml matrigel
TM
.  
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Figure 36 Assessing migration and viability for the potential candidates using the DU145 PCa cell 
line 
(A) The relative wound density observed for each treatment following the DU145 wound scratch 
assay shows that mitoxantrone HCL and zactima inhibited migration (B) The viability data made 
relative to DMSO for each treatment and shows that the two treatments that inhibit migration also 
reduce viability. The error bars represent ±SD of n=3 biological replicates for each treatment. 
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Figure 37 Z-scores calculated for migration and viability assessed using the DU145 PCa cell line  
As mentioned in the previous figure, mitoxantrone HCl and zactima significantly reduce migration as 
well as cell viability. Z-scores beyond the green line represent high confidence significant variation 
(p=0.05) whereas the values between the green and orange lines represent medium confidence 
significant variation (p=0.1).  
 
Figure 38 Wound scratch images taken during the DU145 migration assesment 
The wound scratch images for DMSO, mitoxantrone HCl and zactima at the 0h and 24h time points 
are shown in this figure. DMSO shows 100% wound closure, whereas mitoxantrone and zactima show 
almost negligible wound closure. Changes in cell morphology can be seen in the presence of 
mitoxantrone HCl and zactima that indicate reduced cell viability after 24 hours (10x magnification).  
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This can be seen in the wound scratch images of the negative control (Figure 41). 
For the ease of determining hits and comparing results, the relative wound density of 
all the candidates was normalised to that of DMSO (Figure 39). It was observed that 
mitoxantrone HCl, simvastatin and fluvastatin showed a significantly reduced 
invasion when compared to the negative control. This is confirmed with the Z-score 
values calculated for each candidate (Figure 40). However, the statins (simvastatin 
and fluvastatin) also caused a significant reduction in cell viability post the 48-hour 
treatment. 
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Figure 39 Assessing invasion and viability following a wound scratch invasion assay using the PC-
3
VimRFP
 cells 
A wound scratch invasion assay was performed in the presence of matrigel
TM
. The wound density and 
viability of all treatments was made relative to DMSO for the ease of comparing. (A) Wound density 
for mitoxantrone HCl, simvastatin and fluvastatin is significantly reduced (dotted line; 6SD less than 
the mean of the negative control). (B) Simvastatin and fluvatatin show reduced cell viability after a 
48-hour treatment (dotted line; less than 80%). The error bars represent ±SD of n=3 biological 
replicates for each treatment. 
A 
B 
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Figure 40 Z-scores calculated for the wound scratch invasion and viability assessment 
The migration z-scores of mitoxantrone HCl, simvastatin and fluvastatin show significantly reduced 
invasion. Simvastatin and fluvastatin also show significantly reduced cell viability after the 48-hour 
treatment. Z-scores beyond the green line represent high confidence significant variation (p=0.05) 
whereas the values between the green and orange lines represent medium confidence significant 
variation (p=0.1).  
 
 
Figure 41 Wound scratch images taken for the invasion assay performed using the PC-3
VimRFP
 cells  
Wound scratch invasion images at the 0-hour and 48-hour time points for DMSO, mitoxantroneHCl, 
simvastatin and fluvastatin. The scale represents 300 µm. While DMSO shows 50% wound closure at 
the end of 48 hours, mitoxantrone HCl, simvastatin and fluvastatin show less than 20% wound 
closure.  
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5.4 Discussion  
Thirty-nine drugs were identified as potential candidates that can inhibit the 
migratory properties of the PC-3
VimRFP
 cells using the cell-based multi-parameter 
screen. During the primary screen it was observed that many of the drugs also had 
inhibitory effects on cell viability. Given the nature of many chemo and cytotoxic 
drugs in the library, reduction in viability is not surprising and supports the inclusion 
of the cell viability parameter for clearer interpretation of the data. In addition to this, 
a high concentration of 10µM was used as the screening concentration which could 
also affect the cell viability parameter. Therefore, a dose response study was 
performed to identify lower concentrations of drugs that could be used to inhibit cell 
migration while reducing the effect on viability. At the same time, the dose response 
studies have served the dual purpose of also validating the results obtained in the 
primary screen (at 10µM dose). This resulted in the identification of the optimal drug 
concentration for each of the drug candidates for further studies.  
The first set of dose response studies was carried out using concentrations ranging 
from 10μM to 0.1nM (1 in 10 serial dilutions). However, there was a sharp increase 
in wound closure for many drugs between 10μM to 1μM. For example, in response 
to mitoxantrone HCl there is a dramatic loss of its inhibitory effect on wound closure 
from 20% relative density with 10μM treatment to almost 70% relative with the 1μM 
concentration (Figure 29A). A similar trend was observed with all other candidates 
and very few candidates such as vincristine which measured significant inhibition 
even at 1nM concentration (Figure 29B). As a result, the dose response studies were 
repeated with drug concentrations, 30μM, 10μM, 3μM, 1μM, 0.1μM and 10nM. A 
treatment that has a relative wound density less than 6 standard deviations from the 
mean of the negative control (dotted line; inhibitory concentration) shows sufficient 
inhibition. Figure 30A shows the relative wound density for the different 
concentrations of mitoxantrone HCl. The concentrations up to 3μM show a wound 
density less than the inhibitory concentration and lower concentrations show a 
wound density greater than the inhibitory concentration. At the same time the 
viability was determined for each concentration. Any concentration with viability 
less than 80% was classified as effecting cell viability. We selected 80% as the 
benchmark based on a study performed by a group based in Harvard (Simpson et al. 
2008). Simpson et al (2008) performed a siRNA screen to determine the effectors of 
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cell migration in MCF-10A breast epithelial cells with the addition of AlamarBlue to 
assess the cell viability profile. Mitoxantrone HCl concentrations higher than 3μM 
show reduced viability (Figure 30B). Based on these criteria, 3μM was selected as 
the effective drug concentration. Similarly, the effective drug concentrations for all 
the candidates were determined (Table 11). The dose response study was useful in 
determining the effective concentrations for all the candidates and was useful in 
identifying cytotoxic treatments and treatments that did not show the desired level of 
migration inhibition. One reason to explain the loss of activity by tamoxifen citrate 
could be due to the chemical instability (during freeze-thawing). Due to the time 
limitations for this project, the 18 cytotoxic drugs were excluded from further 
analysis, but will be looked at with great interest in the near future. The optimal 
concentrations determined for the 20 candidates in this experiment were utilised in 
further validation studies.  
After the dose response studies, 20 drug candidates were pursued further. A wound 
scratch assay followed by the PrestoBlue cell viability assay using an alternate PCa 
cell line was performed to determine the effect of drug candidates on another cell 
line. DU145 was selected as the alternate cell line; these cells are highly migratory 
but show a comparatively lower metastatic potential than the PC-3
VimRFP
 cells. The 
results showed that only mitoxantrone HCl and zactima inhibited migration and both 
the candidates significantly affected cell viability. The PC-3
VimRFP
 cell model was 
utilized to determine the optimal concentrations, while it would be ideal to observe 
the same effect on the DU145 cell line; the two cell lines have different properties. 
The two cell lines were isolated from different metastatic lesions and show different 
properties and molecular characterizations (Stone et al. 1978; Pulukuri et al. 2005). 
They were also observed to use a different mode of migration whereby PC-3 cells 
employ a mesenchymal-type migration and migrate as single cells, the DU145 cells 
migrate collectively as a cohesive sheet of cells to fill the wound (Powell et al. 1993; 
Nagle et al. 2011). These differences could be the reason for observing altered results 
when subjected to the same drug treatments at the same concentrations. This is 
apparent by comparing the differences in the relative wound densities and cell 
viability observed for both cell lines post treatment with vorinostat, mitoxantrone 
HCl and zactima. It should be noted that the absolute resazurin data for the controls 
are very similar for both DU145 and PC-3 cells. While vorinostat proved to be 
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cytotoxic for PC-3
VimRFP
 cells, it showed no effect in the migration or viability 
profiles of the DU145 cells. The optimal concentrations of mitoxantrone HCl and 
zactima were determined for the PC-3
VimRFP
 cells based on the condition that they did 
not reduce cell viability; however DU145 cells showed a significantly reduced 
viability post treatment. It should be noted that vorinostat being a HDAC inhibitor is 
known to have contradicting results with respect to EMT (possibly migration) 
amongst the different PCa cell lines as mentioned in the discussion of Chapter 4. One 
way to resolve this issue would be to perform dose response studies and identify the 
optimal conditions for the DU145 cells. The differences in the cell properties could 
make them more resistant/sensitive to some of the drugs. However this can only be 
determined after repeating this assay. Another solution would be to perform similar 
migration and viability studies on several other PCa cell lines to rule out the 
possibility that the inhibitory effect is only observed on PC-3 cells. Transwell or 
xCelligence
TM
 migration and invasion assays can be included to assess another form 
of migration whereby cells are plated and migrate as single cells as opposed to a 
wound scratch assay where cell migration is initiated from a confluent monolayer 
(Limame et al. 2012). 
Invasion of tumour cells plays an important role in penetrating the various host tissue 
barriers, intravasating to the circulatory and lymphatic systems and extravasating at a 
secondary location (Friedl et al. 2003). As a result, the candidates underwent a 
wound scratch invasion assay and a PrestoBlue cell viability test using the PC-
3
VimRFP
 cells. The optimal concentrations determined in the dose response migration 
studies were utilized in this experiment. As opposed to the migration assay, the 
invasion assay is carried out over an extended period of 48 hours and involves the 
addition of a biomatrix, Matrigel
TM
. Matrigel
TM
 is a basement membrane ECM 
extract that supports tumour growth and differentiation (Kleinman et al. 2005). It is 
commonly used to assess the invasiveness of tumour cells by mimicking the nature 
of the tissue barrier that would be present in vivo. Matrigel
TM
 is filled into the wound 
once the scratch has been made and the cells have to invade through the Matrigel
TM 
in order to fill the wound space. The relative wound density metric of the IncuCyte
TM
 
control software can be used to determine the extent of invasion observed (Roddy et 
al.).  
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Mitoxantrone HCl and the statins, simvastatin and fluvastatin, were the only 
candidates that inhibited invasion. While the statins significantly reduced cell 
viability after the 48-hour treatment, mitoxantrone HCl did not affect viability. 
However, while performing the invasion assay, the PC-3
VimRFP
 cells were slightly 
less confluent than desired. This could affect the results obtained from the assay. The 
only way to verify the results obtained would be to repeat the invasion experiment.   
So far, based on the preliminary data obtained from the validation assays, 
mitoxantrone HCl seems to be a consistent candidate that can inhibit migration and 
invasion in the PC-3 cell lines without severely affecting cell viability. However, 
several other studies need to be undertaken to verify this result. Some of the studies 
have been mentioned in Chapter 6 as a part of the future directions stemming from 
this project along with further information on mitoxantrone HCl.  
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Chapter 6: General Discussion 
The metastatic spread of PCa and the development of secondary tumours within vital 
organ sites is responsible for 3000 deaths annually in Australia (AIWH 2013). While 
several treatments are available for men with metastatic PCa, they merely serve as a 
palliative agent and do not significantly improve the life span of the patients once the 
disease has metastasised. With the rise of the ageing Australian population, the 
incidences of PCa are bound to increase significantly. This warrants the need to 
develop better therapies that can either inhibit or prevent the spread of the disease 
and significantly benefit the life span of the patients.  
The acquisition of migratory and invasive properties in tumor cells marks the first 
stage of metastasis. EMT has well established its role in promoting migration and 
metastasis of PCa.  However, there is currently no clinical therapeutic in use that 
directly targets EMT or migration in general. By using the drug repositioning 
strategy one can reduce the high input of time and monetary investments that are 
otherwise required in the traditional de novo drug discovery. Most of the drug 
repositioning screens are carried out on a large scale using high-end and expensive 
computer based systems like robotics and specialised bioinformatics tools, putting 
them beyond the reach of most academic research laboratories. Keeping this in mind, 
we wanted to develop an in-house small scale screening assay that could be 
adaptable to a larger cohort of laboratories. To this end we optimised a cell-based 
multi-parameter primary screening assay, which can identify existing drugs that can 
inhibit the migratory and invasive properties of the metastatic PC-3 PCa cell model. 
This assay can be performed without the requirement of very sophisticated computer 
programs and bioinformatics tools. While it did involve the use of the IncuCyte 
Zoom live imaging system the same analysis could be performed using automated 
live cell microscopy and freely available image analysis tools, such as cell profiler or 
ImageJ.  Chapter 3 has presented the entire process of optimising the various factors 
that need to be addressed to establish an effective screening assay.  
The primary screening assay developed was used to screen a library of 420 FDA 
approved drugs and 39 potential candidates that could inhibit the migratory 
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properties of the PC-3
VimRFP
 PCa cell line were identified. The shortlisted drug 
candidates were classified into high confidence and medium confidence categories 
based on the extent of migration inhibition; several drugs showed reduced cell 
viability and were classified as cytotoxic drugs. The data collected from the primary 
screen and basic information about the 39 candidates has been presented in Chapter 
4. The Z’ Factors calculated in Chapter 4 conclude that the assay developed is of 
excellent quality and reliability (Z’ Factor above 0.5). The cytotoxic drugs, drugs that 
showed an increase in cell viability and drugs that changed cell morphology without 
affecting cell migration were excluded from the present study. While outside the 
specific focus of the current study, this information is still of great importance as 
they may be useful for inhibiting additional biological phenotypes associated with 
metastasis. For example, drugs that demonstrated an increase in viability could be 
useful in further understanding the mechanism that regulates cell growth and 
proliferation in PC-3 PCa cells. Changes in cell morphology could represent an onset 
of cell death and apoptosis. Proliferation studies should be performed for 72h-96h for 
all drugs falling under these two categories. We could also identify candidates that 
increase migration of the PC-3 cells by looking at the wound density data from 
earlier time points. This could help elucidate the pathways responsible for increasing 
migration, following which these pathways can be targeted for therapy. The 
cytotoxic drugs are of special interest as they could potentially be used for targeted 
chemotherapy treatments that kill cancer cells.  
Approximately half of the potential candidates showed a significant reduction of 
viability. This is an expected result as many of the drugs from the library are used in 
chemotherapy and cytotoxic therapies. In addition, it was hypothesised that the 
cytotoxic effect was a result of the high drug concentration used in the primary 
screen. While 10μM is a standard concentration for screening assays (within the μM 
range (Lipinski et al. 2012)), it is much higher than the IC50 values of most drugs 
(not specific to PC-3 cells), it was selected for the ease of performing the screen at a 
single concentration and to ensure that weakly positive candidates that might require 
high concentrations to discern the desired effect of migration inhibition were not 
missed. As a result, dose response studies were carried out to determine if the 
cytotoxic candidates could inhibit migration without significantly reducing viability 
at lower concentrations. This study served the dual purpose of validation by 
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repeating the wound scratch migration assay and helped identify the most optimal 
concentration of each candidate.  
Some of the drugs were excluded due to the lack of the desired level of migration 
inhibition, while some other drugs were identified as cytotoxic drugs post the dose 
response studies and excluded from further validation assays. A number of these 
candidates are already undergoing several clinical trials as a treatment for CRPC and 
androgen independent PCa; some drugs are already being used as treatments for 
different stages of PCa whereas other drugs show no relation to PCa treatment yet. 
Bortezomib, a proteasome inhibitor, is known to be a potent anti-tumour agent for 
numerous haematological cancers, but not for solid tumour types like PCa (Manna et 
al. 2013). Docetaxel, an anti-microtubule compound, is a common chemotherapeutic 
agent used for the treatment of metastatic PCa; however docetaxel resistance is a 
common problem. Various combination therapies are being developed to overcome 
this resistance. Combination therapy with prednisone, a corticosteroid was being 
investigated. The study concluded that while the combination therapy eases pain, the 
addition of prednisone does not significantly improve the life span of the patients 
(Tannock et al. 2004). Mitoxantrone, a type II topoisomerase inhibitor, has been used 
a first line chemotherapeutic agent for treating CRPC (Michels et al. 2006). 
Combination treatments with prednisone are being carried out to determine its 
effectiveness as a second line treatment, which seem to be positive in improving the 
quality of life (Bloomfield et al. 1998).  Dasatinib, a kinase inhibitor and docetaxel 
have undergone phase III trials as a treatment for CRPC, however addition of 
dasatinib did no significantly improve the overall survival of the patients (Araujo et 
al. 2013).  
Albendazole and fenbendazole are broad-spectrum antihelmentic treatments. 
Albendazole in combination with 2methoxyestradiol has shown an anti-proliferative 
effect against DU145 cell line as well as HCT-116, a colorectal cancer cell line in a 
preclinical study carried out last year (Ehteda et al. 2013). Fenbendazole also shows 
anti-tumour activity against PCa cells as mentioned in the patent by Unitech Limited 
(Morris et al. 2005).  Nitazoaxnide is an antiprotozoal drug that has been highlighted 
as a lead candidate in a drug repositioning study carried out for breast cancer (Fan-
Minogue et al. 2013) and a review by Di Santo et al. opens up the possibility of 
targeting epithelial ovarian cancer and possibly other epithelial cancers like PCa. 
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Elvitegravir is used towards the treatment of HIV infections; no associations have 
been made linking elvitegravir to PCa so far. A number of cytotoxic drugs such as 
topotecan and dasatinib were excluded as they just missed the viability cut off or 
showed images of cells that underwent severe stress, but showed significantly 
reduced wound closure. These drugs were excluded from this particular study, but 
should definitely be assessed under validation studies in the future.  Several cytotoxic 
assays could be used to identify drugs that can kill cancer cells. A screening assay 
similar to the one developed by Li et al. (2013) can be used to validate the cytotoxic 
nature of the drugs. The study demonstrates the use of a 3-D cell based fluorescence 
technique as a high throughput screen to identify cytotoxic compounds (Li et al. 
2013). Future studies could test these drugs alone or in combination to kill metastatic 
CRPC tumours alone. The studies could also assess the effect of these drugs on more 
AR+ve cell types like LNCaP cell line. 
Following the exclusion of the cytotoxic and inefficient drugs, 20 remaining drug 
candidates underwent the remainder of the validation studies. These studies included 
performing a wound scratch migration assay using an alternate, DU145, PCa cell line 
and performing a wound scratch invasion assay. As discussed in chapter 5, DU145 
dose response studies need to be carried out to determine the optimal concentrations 
for the candidates that can inhibit migration of the DU145 cells; and the wound 
scratch invasion assays need to be repeated for PC-3
VimRFP
 cells as well as DU145 
cells. However, due to the lack of time and the long waiting periods of the heavily 
booked IncuCyte ZOOM, the DU145 dose response studies and the invasion studies 
could not be performed in the given time frame. Further studies that can be included 
would be to assess the effect of these candidates on a different mode of cell 
migration. For example, xCelligence and Transwell migration and invasion assays 
could be performed to assess the effect of the drugs on single cell migration. The 
Additional cell lines such DUCaP, C42B, LNCaP can be used to further validate the 
findings.  
HDAC inhibitors like vorinostat are currently being used in the treatment of T-cell 
lymphomas; however, they show contradicting results with regards to EMT 
inhibition as mentioned in chapter 4. While some studies suggest they help inhibit 
EMT others suggest they promote EMT (Yoshikawa et al. 2007; Kong et al. 2012). 
As a result, we developed a special interest in vorinostat. However, vorinostat did not 
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make it through the dose response filter as it had a cytotoxic effect on the PC-3 cells. 
While performing the primary screen it was observed that vorinostat inhibited 
migration and reduced viability and promoted a more mesenchymal-like morphology 
of PC-3
VimRFP 
cells (Figure 28). A wound scratch migration assay was performed 
using DU145 cells followed by the PrestoBlue viability test. For DU145 cells, 
vorinostat did not inhibit cell migration nor did it reduce cell viability. Following on 
from this information, we decided to determine the EMT profile following vorinostat 
treatment of PC-3
VimRFP
 cells and the more epithelial LNCaP cell line. Both cell lines 
were treated with vorinostat at the concentrations 1μM and 10μM each. RNA was 
collected 24 hours and 48 hours after treatment for each concentration and cell line. 
cDNA was collected from the respective samples and a qRT-PCR was performed to 
observe changes in the EMT profile for both PC-3 and LNCaP cells.  
The qRT-PCR showed alteration of the EMT profiles for both cell lines. PC-3 cells 
showed an increase in E-cadherin (an epithelial marker) and a decrease in the 
mesenchymal markers (snail. slug, vimentin, twist, NRP1) when treated with 
vorinostat at the lower concentration of 1uM for 24 hours. However, there was an 
increase in all markers when treated with the higher concentration of vorinostat at 
both time points. At the highest concentration, the transcription factors slug and twist 
show a dramatic increase of almost 18-fold at the 48-hour time point. In comparison 
to their more mesenchymal counterparts, the epithelial LNCaP cell line showed an 
increase in all markers at the 24-hour point for both vorinostat concentrations and 
while the epithelial markers remain almost constant, the mesenchymal markers show 
a sudden drop at the 48-hour time point. The relevant data has been presented in 
Appendix C. These experiments need to be repeated and further studies using several 
other HDAC inhibitors need to be performed to confirm the changes in the EMT 
profile of the various PCa cell lines. 
Based on the preliminary results from the validation assays so far, mitoxantrone HCl 
was identified as a strong candidate that can inhibit both the migratory and invasive 
properties of PC-3
VimRFP
 PCa cells. Mitoxantrone HCl is antineoplastic agent that is 
currently used in reducing the number of relapses of multiple sclerosis. It is also used 
along with other treatments as a treatment for acute nonlymphocytic leukaemia and 
advanced PCa (Schuler et al. 1990; Bloomfield et al. 1998). Mitoxantrone HCl in the 
presence of a corticosteroid such as prednisone is known to aid in the palliative 
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treatment of men with symptomatic advanced PCa. However, studies also suggest 
that docetaxel or cabazitaxel show a better survival rate than mitoxantrone HCl (De 
Bono et al. 2010; Tannock et al. 2004). As mentioned before, the exact use and 
timeline of the drug can only be speculated at this stage, but it would be ideal to use a 
candidate that can specifically target PCa migration and inhibit or reduce the 
probability of developing a more advanced and lethal form of the disease. In order to 
use the candidate as a preventive therapy it has to be well tolerated by the patient 
over a long period of time. Mitoxantrone HCl has a very toxic effect on patients and 
therefore may not be suitable. However, it can be used as an adjuvant or a 
combination therapy with existing therapies to increase efficiency in supressing 
metastasis. The past clinical studies show that mitoxantrone HCl is provided at a 
concentration of 12-14mg/m
2
 as a 30min infusion every 21 days (Berry et al. 2002). 
This helps maintain a plasma concentration of approximately 0.8mg/l. Taking the 
average body surface area, 1.91m
2
 (Sacco et al. 2010) the mitoxantrone HCl 
concentration was calculated to be 26.74mg (0.05µM). In general, mitoxantrone 
hydrochloride is tolerated at concentrations as high as 75mg/m
2
 that would equate to 
0.3µM (Canal et al. 1993). The optimal concentration for mitoxantrone HCl 
determined by the dose response studies was 3 µM.  
However, the DU145 dose response studies and the PC-3 and DU145 invasion 
studies need to be repeated to confirm the results and possibly identify other FDA 
approved drugs that could prevent both migration and invasion of the two cell lines. 
Similar wound scratch migration and invasion studies can be performed with a series 
of other PCa cell lines to determine the extent of migration inhibition on other cell 
lines. Three dimensional matrigel
TM
 invasion assays can also be incorporated to 
validate the wound scratch invasion results (Colella et al. 2004). Furthermore, the 
Hollier laboratory has generated cell models that can mimic the dynamic nature of 
EMP in vitro. These cell models could be utilised to determine the effect of the drug 
candidates on plasticity responses of PCa cell. This can be valuable in identifying 
candidates that can inhibit or prevent EMT and/or MET. Most importantly the 
accuracy and reliability of the assay verified has been verified and the assay can be 
used to screen a larger cohort of FDA approved drugs to increase the chances of 
finding the desired compound(s). The Prestwick chemical library (Prestwick 
Chemical, France) comprises of about 1300 drug candidates that has been approved 
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by the FDA and other similar administrative bodies throughout the world. Some of 
the repositioning studies performed by Shahar et al (2014) and Bharadwaj et al 
(2014) were carried out using the Prestwick chemical library. Apart from the drug 
library, the company provides various other screening libraries such as a peptide 
library, a fragment library as well as a phytochemical library that comprises of 
natural compounds (Prestwick Chemical website). The primary screening technique 
can also be applied to phytochemical libraries such as the Nature Bank available at 
the Eskitis Institute, Queensland. This can give us an opportunity to identify a novel 
compound that could potentially inhibit migration of the PCa cells.   
The shortlisted drugs could then undergo in vivo and clinical studies to further 
determine their mode of action in preventing the progression of PCa to the metastatic 
stage. The assay is not limited to FDA approved drugs alone, natural compounds can 
also be screened to identify a novel compound that can inhibit migration and 
invasion of PCa cells. 
In conclusion, a cell-based multi-parameter primary screening assay was successfully 
developed and was used to screen a library of 420 FDA approved drugs. With the 
help of this screen, we have identified a number of drug candidates that can inhibit 
the migratory and/or invasive properties of the PC-3 PCa cells. By using the drug 
repositioning strategy as opposed to the de novo drug development strategy we can 
shorten the candidate’s route to clinical use and significantly improve the life span of 
patients suffering from PCa. 
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Appendix A 
Primary Screening Assay Data 
The mean migration (relative wound density), viability and RFP-vimentin expression 
data has been presented below. The viability and RFP reporter expression have been 
normalised to DMSO for the ease of understanding. 
Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
DMSO 92.03897119 100 100 
Cytochalasin D 19.55730703 99.43529865 136.4925704 
Ethinyl 45.941435 73.8423413 160.3163524 
Urosidol 84.42666 100.4155376 101.3173574 
Ezetimibe 75.37566 94.08619405 93.66087319 
Flurbiprofen 89.90177 99.15971546 103.2889624 
Hydrocortisone 84.309685 94.78945444 112.6877992 
Estradiol 80.552135 101.9225241 115.3049902 
Levonogestrel 90.758845 100.7671678 111.2717898 
Metalozone 89.403585 84.84334317 116.163401 
Nitozoxanide 56.202185 59.27480458 160.4676611 
Nitrofurasone 86.46333 98.95878392 106.8482998 
Enalaprilat 83.982275 99.0090168 98.33872224 
Disulfiram 56.5006 83.48705526 119.0595585 
Torsemide 89.70505 93.33270077 116.9164273 
Gemfibrosil 86.40317 102.6257845 89.54458873 
Triamcinolone 89.67433 90.26849477 109.0029241 
Ketoprofen 91.857455 89.8163988 103.0433294 
Estrone 88.54176 95.9448108 116.90402 
Mesalamine 88.69517 105.7904563 98.29060198 
Piroxicam 87.257975 97.04993428 84.9620912 
Indapamide 88.78118 97.50203025 102.2453371 
Riluzole 70.646085 64.59949042 165.0382411 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Orlistat 69.0305 90.46942631 119.5725937 
Ketorolac 91.93135 100.3653047 112.5433314 
Flucytosine 90.53761 95.54294772 106.1297265 
Ipratropium 89.540015 95.34201618 101.0197331 
Desonide 88.81666 87.65638474 125.7700116 
Glipizide 88.22814 90.11779612 103.8426521 
Risperidone 80.452395 91.12245382 99.07956007 
Allopurinol 90.428935 91.92617998 117.3724498 
Adenosine 88.71351 88.00801494 118.0924995 
Sulfanilamide 81.47325 80.32238349 116.6941665 
Didanosine 88.55029 90.67035785 119.7033671 
Glyburide 81.412945 92.37827595 88.61788493 
Betamethasone 86.39126667 104.919753 99.90980435 
Emtricitabine 88.34152 93.83502962 102.3102756 
Zalcitabine 91.61902 118.6165863 77.4653575 
Cefdenir 94.25520333 110.2779274 84.27168378 
Erythromycin 95.05886 100.1978618 96.39180495 
Telbivudin 86.22013 96.24620811 103.0850069 
Aminophylline 94.23236333 112.6556173 87.2348336 
Methylprednisone 92.87909 96.38016248 105.3273601 
Preogesterone 93.62116333 103.8816067 95.6349339 
Indomethacin 93.94501667 110.0769959 86.91045773 
Clotrimazole 80.18111333 110.0100187 69.74670471 
Prednisone 90.20924 100.4657705 96.33978241 
Ibuprofen 91.71703333 106.7281368 92.54891663 
Monobenzone 81.1488 87.60615185 84.01671735 
Amorolfine 94.32729667 100.4992591 115.795033 
Lamivudin 92.25428 101.8053141 95.26549188 
Paliperidone 93.57992333 100.2648389 97.61652046 
Rizatriptan 94.42449 100.2983275 102.1286466 
Acetylcysteine 90.58138 104.1160268 83.06995829 
Albenzadole 33.61190667 63.2934354 167.6725986 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Tretinoin 90.34914333 103.5132322 82.73938081 
Chloramphenicol 93.57117 105.5225476 89.20359792 
Busulfan 94.72501 100.2313503 103.1725122 
Eplerenone 93.15600667 99.6955329 85.03659092 
Terbinafine 94.54197667 106.5272053 96.17690387 
Pyridostigmin 92.88045 107.531863 88.28737112 
Aldrenoate 90.19279333 95.54294772 91.52219524 
Chlorothiazide 93.57711333 98.08808057 98.86831348 
Phenylbutazone 93.22933 110.3783932 91.04032686 
Carbamazepine 83.46269 100.3987933 88.90954675 
Hydrochlorathiazide 95.29504 95.57643631 103.6338284 
Levodopa 93.29266 99.92995303 95.58970373 
Methimazole 89.43908667 88.07499212 112.0403222 
Cimetidine 83.96814 86.0991653 113.5718197 
Valsartan 82.47595 84.19031566 109.3536342 
Sulfamethoxazole 85.947395 97.04993428 87.65543067 
Pitavastatin 68.756335 74.24420438 231.4562237 
Ethionamide 91.39626 100.7169349 88.89633814 
Acadesine 82.670975 87.65638474 104.3820661 
Clemastine 71.00814 84.59217874 101.4853824 
Dipyridamole 70.51224 84.69264451 102.3704695 
Sulfisoxazole 90.220935 96.54760543 97.1703601 
Metformin 85.60042 99.46111277 92.48796141 
Rifapentine 88.39194 98.75785238 95.90596113 
Trifluride 82.1228 101.6211268 71.95747883 
Daidzen 86.09051 104.7857986 86.69325723 
Hydroxyurea 86.45246 99.26018123 90.90490405 
Methoxsalen 81.955795 97.55226313 96.60173283 
Pyrazinamide 86.66334 98.45645507 93.41198101 
Vidarabine 87.0822 95.79411215 84.67039797 
Acipimox 80.938185 92.93083769 98.50740325 
POtassiumIodide 84.164515 101.0183322 89.22682284 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Miconazole 81.94971 95.99504369 87.9750421 
Haloperidol 83.6635 105.941155 87.72141504 
Quetiapine 84.181195 93.08153634 91.79197289 
Teniposide 52.34062 90.62012497 106.6907049 
Acyclovir 88.490485 98.85831815 86.56676989 
Diphenylhydramine 82.45294 104.4341684 85.73337687 
Tropisetron 68.82211 101.7215926 88.72274845 
Primidone 94.958725 99.10948257 97.29772729 
Amiloride 85.038615 93.68433097 79.21749057 
Dapoxetine 67.59057 98.35598929 77.72152131 
Nicotinamide 86.931295 101.4201953 95.63309935 
Triamcinolone 84.066895 93.08153634 112.0485349 
Nefiracetam 90.52332 99.41087988 97.99375515 
Nisoldipine 60.74771 58.93991868 133.5378122 
Cefditoren 85.85067333 94.10293834 84.581784 
Rifamixin 84.006825 95.34201618 109.2770702 
Amoldipine 70.225795 91.15594241 82.73681577 
Nystatin 77.59123667 95.71039067 103.6617503 
Lglutamine 85.54349 92.79688333 97.09093476 
Sulfadiazine 82.96004333 94.03596116 89.6965002 
Simvastatin 56.36567 74.61257887 182.799518 
Clofibrate 86.02290333 94.06944975 97.37002898 
Felodipine 82.39510667 68.98649573 132.9948646 
VitB12 84.43287667 100.1308846 83.09621287 
Isonaid 86.75190667 95.81085644 86.05513 
Chlorprothixene 55.21925333 98.99227251 81.25423062 
Ramipril 88.32064667 99.12622687 82.01007928 
Chloroxine 71.79888 86.90289146 82.6122934 
Deflazacort 85.83738667 97.01644569 112.7108465 
Diclofenac 90.01289667 108.0676804 81.78072193 
Levamisole 87.69818333 100.0304188 91.58680533 
Gadodiamide 85.78627333 98.25552352 78.91677513 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Oxytetracycline 83.32361667 98.05459198 85.87844194 
Fenofibrate 84.70737667 103.8146295 76.54564997 
Lomustine 83.68318667 99.52808995 79.37488155 
Nizatidine 90.02656667 101.8388027 78.99751298 
Levoflaxacin 83.6054 103.9820724 90.19139609 
Thioguanine 57.11238333 80.17168484 122.0054313 
Ranolazine 86.28071 99.22669264 89.28773355 
Chenodeoxycholic 86.03839667 101.7718255 83.06288476 
Carbidopa 82.829595 95.34201618 97.24909715 
Fluvastatin 60.86472667 75.01444195 214.407236 
Enalapril 88.23739667 100.097396 87.68024832 
Oxybutinin 84.16179667 98.99227251 90.71508838 
Toremifene 39.02525 85.49637067 104.5233332 
Ranitidine 85.80679667 99.42762418 88.98412311 
Taurine 90.88889333 102.5755517 120.0192823 
Atropine 92.02281 105.9244107 107.1339872 
Domperidone 84.74674333 109.4742012 116.6845421 
Manidipine 76.84664667 96.11225375 162.6081027 
Ozagrel 94.44983 104.6518442 109.7760867 
Terbinafine 95.05048 105.5560362 131.387235 
Nilotinib 91.30671667 91.75873703 139.6645362 
Prami 94.05390667 103.7811409 126.9494475 
Gaba 95.21817 109.407224 109.0273861 
Donepezil 92.98315 108.8714066 100.282857 
Milrinone 95.91825333 106.3262738 120.3546784 
Pancuronium 91.14259667 107.9672147 111.8369232 
Vardenafil 95.19101333 115.703079 110.7490766 
Pazopanib 64.17927 59.77713343 196.990823 
Amantadine 97.0915 104.8862644 113.3945977 
Mitoxantrone 22.11091 41.5258518 455.6732844 
Rapamycin 75.75091333 85.59683644 60.48423725 
Amphebutamone 93.79338 109.2397811 99.3032442 
 136 Appendices 
Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Moroxydine 94.29354 91.25640818 107.1190196 
Quinine 88.68062333 100.3987933 93.02589991 
Axitinib 95.11387667 101.0685651 148.6533121 
Sorafenib 39.36087667 70.72790241 156.3695767 
Dextrose 96.34544667 106.962557 115.1148083 
Benserazide 92.49808333 109.6751328 89.485358 
Fenbenzadole 45.80472333 91.28989677 145.6629918 
Mycophenolic 59.23252 91.8592028 163.8370486 
Bortezomib 25.92018333 29.03460767 454.2496928 
Racedrotil 97.36134333 104.8862644 118.0663061 
Sutent 89.8612 93.73456385 105.899466 
Bupivacaine 93.67903 104.1160268 104.6255984 
Fleroxacin 95.71838 106.3932509 102.8311141 
Dasatinib 21.93992667 85.7642794 222.9680834 
Torisel 73.83733333 75.41630504 70.34255914 
Mestranol 85.438675 97.18388864 89.21738695 
Bethanecol 96.53536 98.30575641 96.95993013 
Flaxedil 89.78421333 102.2071772 94.24093737 
Starlix 93.65549 113.2751562 99.62943811 
Rosiglitazone 92.91414667 97.21737723 103.3880842 
Erlotinib 89.55686667 110.9476992 92.25395625 
Zactima 63.59821667 93.53363231 129.9277526 
Flivas 86.20174 96.17923093 104.3043935 
Sonazine 57.25953 96.81551415 105.8241461 
Gleevac 95.58689333 113.5263206 119.1360373 
Prostigmin 91.58026333 106.1923194 101.7221687 
Albuterol 91.12531667 110.4118818 135.8711612 
Iressa 85.37239333 101.3699624 93.02329066 
SAHA 68.16405667 67.01066891 218.0255838 
Rolipram 90.33998667 103.8816067 114.074395 
Dalacin 91.31635667 100.097396 119.2458416 
Lincocin 89.46846667 105.0537073 107.6381657 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Albamycin 89.94776 108.5365207 95.09140686 
Sotalol 91.82918333 104.015561 104.6843389 
Imatinib 88.31156 103.2118349 134.9323855 
Masitinib 85.98382667 101.4369396 116.7474688 
Catapres 94.78296667 107.1969771 101.8870777 
Loperamide 88.80250333 103.6471865 97.82934364 
Opatanol 93.70819333 106.0918536 112.4534777 
Spectino 91.19550333 104.183004 103.1009151 
Tykerb 92.02129 104.8862644 106.2940591 
Abiraterone 86.63930333 97.28435441 116.79748 
Fudostein 94.87287333 107.9672147 105.3564368 
Clozapine 92.74945333 106.9290684 102.7140826 
Manidipine 91.26103667 107.9002375 97.20725061 
Oxymeta 93.9628 100.5327477 114.2124274 
Lenalidomide 96.66311667 98.89180674 115.6268987 
Pemetrexed 90.15357667 87.63964044 100.047955 
Fludarbin 91.32507667 96.41365107 102.65975 
Nepafenac 94.29173 95.74387926 115.7815156 
Benazepril 96.9914 95.44248195 119.7945224 
Streptozotocin 94.42801333 89.64895585 127.7891028 
Glimepiride 98.06971667 100.9346107 112.848003 
Capecitabine 94.07421 99.99693021 113.6896463 
Irinotecan 48.72507 90.15128471 103.1360189 
Carboplatin 95.02752 97.01644569 110.5415582 
Topotecan 56.68590333 85.59683644 159.5183941 
Rufinamide 97.22089333 91.79222562 128.8620428 
Budesonide 97.48264 95.77736785 143.2000051 
Zoledronic 92.07107667 96.94946851 123.2003005 
Granisetron 80.09010667 89.41453572 119.589418 
Cisplatin 96.68064333 97.25086582 131.0302477 
Cladribine 91.22059333 99.12622687 114.3595448 
2methoxyestradiol 33.43084 93.13176923 133.5851793 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Posaconazole 69.67454 93.33270077 133.5889278 
Bumetanide 97.10845 92.26106589 130.1467442 
Dexamethasone 96.87767333 93.83502962 138.6490367 
Decitabine 91.35689333 97.78668326 120.4841136 
Clofarabine 91.11432667 95.24155041 165.2985371 
Letrozole 97.18018333 96.38016248 117.0522 
Prasugrel 93.52038667 100.666702 117.7334008 
Camptothecin 70.25453333 90.21826189 142.007713 
Doxazosin 94.61162333 95.10759605 118.3287494 
Ivermectin 89.65162 71.53162858 180.96809 
Ritonavir 81.3385 97.82017185 98.98056865 
Dutasteride 96.90145 97.41830877 115.8229974 
Dacarbazine 96.68079 98.62389802 117.4973348 
Leucovorin 95.75905667 92.16060012 124.1060108 
Ramelteon 91.68964 98.82482956 115.0632826 
Cetrezine 95.64158 97.45179736 110.8347451 
Etodolac 95.24323333 94.9401531 123.7396133 
Ketopconazole 73.99939333 97.04993428 94.78155966 
Anastrozole 90.64593333 101.3699624 96.36609133 
Bisoprolol 94.30004333 98.02110339 109.1816341 
Dexrazoxane 88.94934333 97.58575172 101.1811234 
Methazolastone 95.40109667 104.2834698 98.80923092 
AMG-073HCl 75.9875 98.42296648 96.3798761 
Clinidipine 92.48563667 102.3076429 98.29786868 
Etomidate 87.27184667 101.2025195 100.6938057 
Lansoprazole 89.96266667 99.79599867 108.6204429 
Aprepitant 73.45817333 97.48528595 97.19611335 
Doxorubicin 41.96318333 83.98938412 180.5654099 
Epirubicin 36.78833667 88.8117411 159.2680863 
Vincristine 52.15885333 94.00247257 153.8083123 
Celecoxib 71.1142 99.05924969 109.4283999 
Cilostazol 91.97336667 99.39413559 106.297672 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Flucanazole 91.69715 98.85831815 103.193088 
Lidocaine 92.13376667 102.0397342 92.08149643 
Bicautamide 91.78798667 101.8722913 95.34639121 
Adrucil 90.56775 101.1020537 97.26299325 
Oxaliplatin 84.31726333 104.183004 88.87269782 
Agomelatin 93.80357 96.68155979 106.2152127 
Acarbose 95.8379 103.5802094 97.66912569 
Floxuride 63.68578 78.22934661 165.3400744 
flumazenil 94.92050667 98.59040943 106.0981329 
Loratadine 92.07367667 100.1643732 98.34375924 
Fulvestrant 90.09465 100.1308846 94.77867793 
Imiquimod 89.30426667 100.2313503 100.6655063 
Etoposide 91.92636333 100.0304188 83.98438035 
Leflunomide 92.78350333 101.7383369 88.76853389 
Adapalene 69.29676 89.54849008 136.9212957 
Ifosomide 74.56182 98.92529533 101.0244649 
Fluxetine 87.59927333 101.2694966 81.55328948 
Biapanem 90.80611 97.08342287 108.4217932 
Methylprednisone 77.22808 67.16136756 130.7648977 
Mesna 88.22807 67.41253199 130.078817 
Methocarbamol 88.13977 86.35032972 106.2958349 
Prednilosone 85.615885 82.58286333 114.4108061 
Telmisartan 80.42344 77.15771172 96.63406267 
Guaifenestin 89.70341 92.67967326 91.18961359 
Rifabutin 79.81685 73.28977956 127.9714491 
Nevirapine 82.765215 74.74653323 106.6762842 
Niacin 83.003535 82.78379487 95.77731863 
Nimodipine 84.894325 86.0991653 97.75912229 
Nicorandil 82.793545 83.58752104 85.22178136 
TamoxifenC 51.679195 77.10747884 114.2072285 
SodiumB 87.951315 84.84334317 82.57327711 
SodiumO 79.875485 76.50468422 87.81468053 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Elvitegravir 40.66858 52.34266642 150.2146191 
Maraviroc 82.28776 83.0349593 95.60993632 
Vicriviroc 90.036845 89.41453572 90.18740508 
Raltegravir 88.72194 81.62843851 101.577566 
Pyrimethamine 76.0269 58.92317438 88.61912313 
Sulindac 86.05088 65.95577832 117.0984294 
Paclitaxel 28.15599 64.14739445 129.8344201 
Finasteride 66.8148 76.05258825 98.97306395 
Bleomycin 76.765795 73.89257418 127.7004403 
Daptomycin 94.618305 101.8797659 108.5275776 
Roncuromium 96.0091325 106.614648 110.1540013 
Risedronate 92.0153875 112.6263522 102.3825924 
Zonisamide 88.4342075 108.2638766 110.345888 
Perindropil 90.9330225 105.0186203 116.5286969 
Pimobendan 71.5924025 66.66075545 124.9790893 
Doripanem 84.20604 99.53892534 103.6464612 
Stavudine 96.92649 102.9969853 114.9585476 
Irbesartan 96.5128525 98.79411243 103.5117715 
Tazarotene 92.2562875 107.4658627 100.2091072 
Dorzolamide 95.474505 108.4234793 103.9047701 
Tenofovir 89.548235 98.10250044 105.5994612 
Sidenafil 85.0460425 124.4369569 103.6741371 
Ofloxacin 93.4083225 107.4126618 98.57438067 
Norfloxacin 93.439085 95.65525802 102.3927403 
BIBR953 89.308345 103.8482 103.9721149 
Gestodene 93.51346 114.5415854 119.4752638 
Trilostene 95.8356125 109.9663061 115.0544909 
Sumatriptan 93.700425 109.2214932 96.93873158 
Tadalafil 85.52156 101.2945558 105.2728849 
BIBR1048 74.6678 105.231424 104.5450073 
Drosperidone 92.71907 106.1890406 101.8475239 
Bimatoprost 93.34974 102.7309807 116.0111565 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Moxifloxacin 92.640465 123.4261394 101.5393983 
Artemether 75.7032925 108.3702784 114.393958 
Isotretinoin 95.8349625 96.29366909 97.5116239 
Linezoid 95.76869 100.6561447 105.2941032 
Topiramate 93.3487425 100.8689484 101.0725971 
Natamycin 91.55334 100.443341 105.607764 
Lopivanir 78.182645 102.9437844 100.6417747 
Alfuzocin 94.173385 101.826565 97.11954784 
Tranilast 94.5739775 94.69764143 105.607764 
Iloperidone 95.4183175 107.0402554 101.1685404 
IbuprofenL 91.87243 97.69434809 105.8999012 
Mianserin 96.281295 94.48071822 124.449817 
Clopidogrel 94.5395075 98.24525607 105.124269 
Venalafixine 92.9088525 96.37829014 104.2740567 
Fludarabine 96.1679675 97.5107121 94.58424746 
Minoxodil 97.8445225 93.01163028 107.098775 
Voriconazole 96.4891175 98.91858804 107.0596205 
Mycophenolate 94.696755 81.99347072 77.35066904 
Omeprazole 96.32991 98.49010406 104.8744259 
Ranolazine 90.7937375 99.37767802 99.05159073 
Zileuton 96.733075 95.67435217 104.4884743 
Dyphylline 95.324135 92.00163232 110.7550606 
Febuxostat 85.9292125 100.785554 93.50097265 
Resveratrol 73.09836 95.27647419 89.30211745 
Replaginide 95.51358 100.632524 100.1348655 
Ziprasidone 98.297845 94.75617221 89.8241776 
Aztreonam 94.239015 95.49071618 100.4443726 
Nebivolol 94.827295 96.95980412 87.07963282 
Docetaxel 90.94925 75.26015099 114.6425442 
Thalidomide 95.789485 96.47010814 103.9067501 
Bendamustine 96.1845 100.112222 92.76635944 
Evista 91.9273775 97.75556009 118.9551339 
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Drug  
Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Entecavir 96.8646275 98.76555805 92.14734526 
Altrtamine 93.2554375 97.4188941 98.29833252 
Megestrol 73.550685 98.55131606 116.9041833 
Gabapentin 91.8038225 92.85860029 106.3809423 
Gemcitabine 89.8479075 84.50316262 78.33512533 
Exemestane 89.1491875 101.091614 109.2448151 
Nelarabine 93.150125 100.326464 102.3200602 
Idarubicin 90.403975 53.46867986 144.6032032 
Asenapine 75.7151075 92.5525403 97.15539369 
Mercaptopurine 93.685585 77.5862069 100.4630176 
Gatifloxacin 93.821085 99.37767802 85.84160446 
Fenoprofen 88.547205 87.66328012 93.87643764 
Esomeprazole 53.55256167 87.08272859 107.5578703 
Ribavarin 91.25301667 102.0803096 104.774577 
Econazole 88.24305667 102.0803096 103.7592697 
Aminolevulinic  89.53544833 87.85679729 106.0686895 
Prednisolone 91.44482 108.1761006 131.7539664 
Erdosteine 91.68699167 97.33913885 105.0809772 
Festerodine 80.125105 96.85534591 107.9337338 
Scopalomine 90.249175 107.4987905 105.9097801 
Miconazole 86.89399667 111.9496855 95.93084111 
Clarithromycin 91.80442833 94.82341558 105.7917875 
Adenine 89.69667833 114.0783745 97.68645686 
Abiraterone 85.575005 103.9187228 112.1881284 
Maprotilline 87.071075 84.27672956 71.39979827 
Lomefloxacin 89.73605333 106.5312046 106.6110748 
Rosiglitazone 89.59480167 99.85486212 106.284692 
Tetracaine 91.75740667 100.2418965 102.9970756 
AdenineH 82.85626667 95.01693275 96.02885109 
Grapeseed 36.32625333 88.5341074 91.99997463 
Naphazoline 88.46548167 107.2085148 99.7598914 
Riboflavin 87.925895 92.50120948 105.3483636 
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Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Trazodone 70.33821333 87.27624577 93.03811922 
Cadesartan 88.90871 113.8848573 97.28299828 
Epinephrine 91.85034333 96.9521045 129.5615877 
Clomipramine 85.80514333 98.88727625 99.28601788 
Cortisone 83.684065 112.5302371 105.7308881 
Tioxolone 79.56571667 93.75907112 96.72919429 
Aliskiren 85.53518167 87.66328012 95.09918357 
Ladrenaline 92.232065 106.1441703 130.2029346 
Cefprpzil 33.94262 99.85486212 98.53524236 
Clomifene 60.91114333 87.27624577 91.47757189 
Flucinonide 91.18601333 101.1127238 112.2290452 
Afazanavir 94.02332167 89.3081761 94.0543781 
Cytarabine 90.95069 102.8046422 133.5333202 
Loteprednol 86.98346 93.42359768 140.8379324 
Divalproex 92.80505667 104.8355899 108.5049059 
Adefovir 93.14819 106.4796905 96.09802088 
Furosemide 91.592825 105.8027079 117.7837981 
Prilocaine 93.21541 93.32688588 121.0079336 
Zolmitriptan 94.622145 107.5435203 93.75258523 
Aminocarproic 96.06471 98.45261122 118.3852492 
Isoprenaline 80.68567333 102.2243714 120.8447146 
Eltrombopag 85.39882 114.6034816 98.25340692 
Olanzapine 94.83099667 102.6112186 138.6378288 
Ritodrine 93.9275425 108.8007737 90.32051306 
Azelastine 65.77703 96.32495164 94.51949126 
Neomycin 69.47092167 100.0967118 111.5658224 
Resperine 86.14972 103.2882012 104.4691468 
Sulfameter  87.961405 97.00193424 111.590417 
AllopurinolS 92.99146333 94.00386847 116.9252211 
OhenytoinS 94.051245 113.2495164 97.46414211 
Tiotropium 84.08002 100.3868472 100.5742479 
Hydralazine 93.038035 98.54932302 127.4562047 
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Candidate 
Relative 
Wound Density 
(%) 
Viability relative 
to DMSO (%) 
RFP expression 
relative to DMSO 
(%) 
Clorsulon 89.199045 98.64603482 92.13157395 
OSI-420 94.56243167 76.40232108 70.27810591 
Phenytoin 85.7865775 118.27853 85.14669221 
TiotropiumBH 95.2111275 99.7098646 100.6189655 
Cloxacillin 93.187755 98.74274662 101.6407615 
IrinotecanH 93.794755 98.83945841 57.28989272 
MethacyclineH 95.810605 93.42359768 91.20144885 
Tropsium 95.59007333 94.77756286 105.2584116 
Amoxicillin 88.8689625 98.83945841 94.58880347 
Apatinib 94.546225 90.90909091 96.55861167 
Itraconazole 92.322255 78.62669246 75.82308246 
Tolterodine 93.964145 96.03481625 107.9951258 
DopamineH 95.846435 96.90522244 99.64412281 
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Appendix B 
Dose Response Study Data 
The relative wound density and viability data determined for all 39 candidates are 
presented below. Following the selection criteria explained in chapter 5.3.1, the 
optimal concentrations for all the drugs were determined. These concentrations are 
presented in Table 11. The dose response studies were carried out for a range of 
concentrations, 30μM to 0.1μM. The dotted line for the wound density data 
represents the inhibitory concentration (6 standard deviations from the mean of 
negative control) and the dotted line for the viability data represents the cytotoxic cut 
off. 
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Appendix C 
Vorinostat EMT profile 
 
Figure 42 Comparing PC-3
VimRFP
 and DU145 vorinostat data 
(A) This graph compares the relative wound density of the indicated treatments between PC-3
VimRFP
 
and DU145. While significant reduction in migration is observed for the PC-3 cells, DU145 cells do 
not show any inhibition. (B) This graph represents the viability made relative to DMSO for the 
indicated treatments. While the viability is significantly reduced for the PC-3 cells, the DU145 cells 
show no reduction in viability (no error bars, n=1). 
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Figure 43 qRT-PCR data obtained after treating PCa cells with vorinostat 
(A) The qRT-PCR data was made relative to DMSO for PC-3 cells post treatment with vorinostat at 
different concentrations and at different time points as indicated. The mesenchymal markers show a 
decreasing trend whereas the epithelial markers show an increasing trend except for EPCAM, which 
shows a decrease at the 24-hour time point and then an increase at the 48-hour time point. (B) The 
qRT-PCR data made relative to DMSO for LNCaP cells post treatment with vorinostat at different 
concentrations and at different time points as indicated. Different trends are observed within the 
epithelial and mesenchymal markers (no error bars, n=1).  
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